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Objective: Inflammatory bowel diseases cause significant morbidity and mortality. Aberrant 
NF-κB signalling is strongly associated with these conditions, and several established drugs 
influence the NF-κB signalling network to exert their effect. This study aimed to identify drugs 
which alter NF-κB signalling and may be repositioned for use in inflammatory bowel disease. 
Design: The SysmedIBD consortium established a novel drug-repurposing pipeline based on 
a combination of in-silico drug discovery and biological assays targeted at demonstrating an 
impact on NF-kappaB signalling, and a murine model of IBD. 
Results: The drug discovery algorithm identified several drugs already established in IBD, 
including corticosteroids. The highest-ranked drug was the macrolide antibiotic 
Clarithromycin, which has previously been reported to have anti-inflammatory effects in 
aseptic conditions.  
Clarithromycin’s effects were validated in several experiments: it influenced NF-κB mediated 
transcription in murine peritoneal macrophages and intestinal enteroids; it suppressed NF-κB 
protein shuttling in murine reporter enteroids; it suppressed NF-κB (p65) DNA binding in the 
small intestine of mice exposed to LPS, and it reduced the severity of dextran sulphate 
sodium-induced colitis in C57BL/6 mice. Clarithromycin also suppressed NF-κB (p65) nuclear 
translocation in human intestinal enteroids. 
Conclusions: These findings demonstrate that in-silico drug repositioning algorithms can 
viably be allied to laboratory validation assays in the context of inflammatory bowel disease; 
and that further clinical assessment of clarithromycin in the management of inflammatory 
bowel disease is required. 
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Inflammatory bowel diseases (IBD) affect 0.5-1.0% of people in the Western world and cause 
substantial morbidity and cost to society(Feagan et al., 2014; van Deen et al., 2014). The 
aetiology of IBD is complex. There are aberrant inflammatory responses, leading to mucosal 
damage and the disease phenotype.  
Diverse therapeutic approaches are employed: Many patients with mild ulcerative colitis are 
treated with mesalazine preparations, which predominantly act topically on the colonic 
mucosa to suppress inflammation(Marteau et al., 2005), others require systemic therapy with 
highly-specific biologic agents targeting inflammatory mediators(Baert et al., 1999; Targan et 
al., 1997). While these drugs have very different mechanisms of action, they influence host 
inflammatory responses and either directly or indirectly alter NF-κB signalling. 
The NF-κB signalling network is a tightly-controlled, dynamically-regulated signal transduction 
pathway with several well-described transcription regulatory feedback loops(Lev Bar-Or et 
al., 2000): this orchestrates innate immune responses by regulating transcription through 
dimers of the five NF-κB proteins (RelA(p65), RelB, NF-κB1(p50), NF-κB2(p52) and c-Rel). 
Signalling through this network is characterised by the oscillation of NF-κB proteins between 
the cytoplasm and nucleus; most clearly demonstrated for the RelA(p65) subunit(Nelson et 
al., 2004). In addition to changes in the inflammatory milieu, this network also affects several 
other processes which are dysregulated during chronic gastrointestinal inflammation 
including cell turnover, DNA damage responses and cell senescence(Perkins, 2012). Several 
studies have associated aberrant NF-κB signalling with IBD (reviewed in refs(Atreya et al., 
2008; McDaniel et al., 2016; Merga et al., 2016)). 
Because of the complexity of NF-κB signalling, targeting specific components of the network 
has not been a successful drug development strategy to date, mainly because of the 
ubiquitous nature of NF-κB signalling. The impact of gross inhibition of critical members of 
5 
 
the NF-κB signalling cascade has been unpredictable and associated with undesirable off-
target effects. The complexity of NF-κB signalling during GI tract inflammation is elegantly 
demonstrated by murine work. When transgenic mice lacking specific NF-κB sub-units were 
subjected to a DSS model, mice lacking cRel and Nfkb1 developed more severe colitis than 
wild-type controls, whilst Nfkb2-/- mice were resistant to colitis(Burkitt et al., 2015). C57BL/6 
mice lacking IKKbeta in epithelial cells were more severely affected by DSS colitis(Greten et 
al., 2004), whilst IL-10-/- mice lacking IKKbeta in the intestinal epithelium had similar colitis 
to those with intact NF-κB signalling but in both these models loss of IKKbeta in myeloid cells 
attenuated colitis and improved survival(Eckmann et al., 2008). It is therefore likely that the 
transcriptomic effects of attenuating NF-κB signalling in the epithelium and myeloid 
compartments is different,  
This complexity has promptied calls for highly specific inhibitors which target components of 
the network in precisely-selected cell types(Baud and Karin, 2009). This approach is useful in 
certain circumstances such as multiple myeloma, where targeting a specific cancer cell lineage 
is desirable and may be achievable. In contrast, for complex benign inflammatory diseases, 
including IBD, this strategy is less likely to be successful due to challenges in identifying a 
specific target cell population. 
We propose an alternative strategy, to ‘nudge’ an individual’s NF-κB signalling network 
towards an idealised healthy phenotype. This approach may offer a more pragmatic way of 
targeting aberrant NF-κB signalling, without the limitations of selective tissue targeting or 
gross pathway inhibition.   
To investigate this in the context of inflammatory bowel disease, we used a combination of 
novel bioinformatic analyses and laboratory studies to identify agents likely to impact NF-κB 
signalling and inflammatory bowel disease. Because of the divergent roles of myeloid and 
epithelial NF-κB signalling during GI tract inflammation, we have established assays to 
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measure the effects of drugs on both epithelial and immune tissues. We then validated the 
efficacy of the most highly ranked agent, both in terms of inhibiting NF-κB activity, and 
modulating an in-vivo model of colitis. 
Methods: 
Pathway analysis for master regulator search 
Molecules that regulate the expression of differentially expressed genes through control of 
the activity of NF-κB sub-units were defined as master regulators and were identified by 
applying a key-node analysis algorithm(Kel et al., 2006) using the TRANSPATH® database of 
gene regulatory and signal transduction pathways(Krull et al., 2006).  
Key-nodes were prioritised based on the weighted ratio between the number of molecules 
from the input set that could be reached from the key-node in ≤10 steps and the total number 
of reachable nodes. The higher the score, the greater the chance that the key-node plays a 
master regulatory role.  
In-silico drug discovery  
Relationships between the chemical structure of compounds and their biological activities 
were analysed using large-scale prediction of activity spectra(Filimonov et al., 1995; Poroikov 
et al., 2001) (http://genexplain.com/pass/) to discover potential new drugs for IBD treatment. 
The PASS algorithm is based on Bayesian estimates of probabilities of molecules belonging to 
the classes of active and inactive compounds(Filimonov et al., 2014). The predicted activity 
spectrum is presented in PASS by the list of activities with probabilities "to be active" Pa and 
"to be inactive" Pi calculated for each activity.  
For each compound of the tested library, a cumulative score was computed across the 46 







here pa(i) is the probability for the given compound to be active for each activity i. 
For each compound tested, the cumulative score was required to be higher than 3.0, and the 
Pa for the PASS activity “Transcription factor NF-κB inhibitor” was positive.  
Patient recruitment and ethics 
Samples used for the generation of human enteroids were donated by patients without 
evidence of IBD attending for colonoscopy at the Royal Liverpool and Broadgreen University 
Hospitals NHS Trust. Samples were collected following written informed consent and 
favourable ethical opinion from North West-Liverpool East Research Ethics Committee 
(15/NW/0045). 
Animal maintenance and welfare 
All animal breeding, maintenance and procedures were performed under a UK Home Office 
licence, with local Animal Welfare and Ethics Review Board approval. Transgenic animals were 
maintained at the University of Manchester. Wild-type mice were purchased from Charles 
River (Margate, UK) and maintained either at the University of Manchester or University of 
Liverpool in SPF facilities with access to standard chow and drinking water ad-libitum unless 
otherwise specified. Standard 12-hour light/dark cycles were used; standard temperature and 
humidity levels were maintained. 
Transgenic mouse strains 
Human TNFα luciferase mice (hTNF.LucBAC) 
This line has been engineered to have a bacterial artificial chromosome (BAC) expressing 
luciferase under the regulation of the entire human TNF promoter. Primary cultures 
established from this mouse enable direct measurement of TNF promoter activity in a non-
transformed ex-vivo system(Minshawi et al., 2019). 
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Human p65-DsRedxp/IκBalpha-eGFP mouse (p65-DsRedxp/IκBalpha-eGFP). 
This line expresses fusion proteins of NF-κB(p65) and the Discosoma red fluorescent protein 
– Express (DsRedxp) under the regulation of the native human p65 promoter, and IκBalpha 
and enhanced green fluorescent protein (eGFP), regulated by the human IκBalpha 
promoter(Dudek et al., 2017). Primary cultures established from this mouse enable direct 
visualisation of these fusion proteins. 
Peritoneal macrophage isolation, in vitro culture and luciferase assay 
Resident peritoneal macrophages were obtained from mice by standard methods. Cells were 
stimulated with either 10ng/mL LPS (Salmonella enterica serovar Minnesota R595; 
Calbiochem), TNF (R&D Systems) at 40 ng/mL, muramyl dipeptide (MDP, Invivogen) at 
10μg/mL or Flagellin (Novus Bio) at 500ng/ml. Luciferase activity was measured over time in 
a CO2 luminometer (Lumistar Omega, BMG Labtech). 
Flow Cytometry 
Peritoneal macrophages were stimulated with 1μg/ml LPS for 20min. Fixed cells were stained 
for phosphor-p65 (PE Mouse anti-NF-κB p65 (pS529), BD Bioscience, clone K10-895.12.50) 
and analysed by flow cytometry using an LSRII Cytometer (BD). Data analyses were performed 
with FlowJo887 software (Tree Star). 
Primary Epithelial cell culture 
Enteroids were generated from human and murine tissue using modifications of established 
protocols. Tissue samples were disaggregated by calcium chelation in EDTA followed by 
mechanical disaggregation in a sucrose/sorbitol solution. Crypt pellets were resuspended in 
Matrigel (Corning, UK) and were maintained in media containing a combination of 
recombinant growth factors and growth factor containing conditioned media (supplemental 




Enteroids were pre-treated with 10μM clarithromycin or 1% v/v DMSO (vehicle) for 30mins. 
Following pre-treatment, 100ng/mL recombinant human TNF (Peprotech) was applied for a 
further 30mins. Fixed enteroids were transferred into Richard-Allan™ Histogel™ 
(Thermofisher) and processed for histology. Immunohistochemical analysis was performed to 
visualise p65 (Cell Signaling Technologies, #8242). The proportion of cells nuclear stained for 
p65 was quantified using manual cell counting. First, for one tissue section of an organoid all 
nuclei were counted using a handheld tally counter. Immediately afterwards, the same section 
was scored for number of positively stained nuclei and the percentage calculated. The 
individual scorer was experienced in quantitative histology techniques (KL) and blinded to the 
experimental conditions for each sample.Murine intestinal organoid confocal microscopy 
Proximal enteroids from p65-DsRedxp/IκBalpha-eGFP dual-reporter mice were passaged into 
glass-bottom dishes (Thermo Scientific™ Nunc™ Glass Bottom Dishes) in phenol red-free 
complete media. Images were taken for 6-8 enteroids per dish using a Zeiss Laser Scanning 
Microscope (LSM880) with a C-Apochromat 40x/1.2 W Korr FCS M27 objective. Enteroids 
were imaged for 30mins before treatment with 10μM clarithromycin or 1% v/v DMSO vehicle. 
Thirty minutes later, cultures were stimulated with 100ng/ml TNF and imaged for a further 
3hrs. Images and videos were processed using Zen 2011 software and CellTracker (Warwick 
Systems Biology Centre). 
LPS-induced NF-κB activation in mice 
Groups of adult (8-10-week-old) male C57BL/6 mice received 50mg/kg clarithromycin i.p, or 
vehicle daily for three days. Following a 3-day washout period, either 50mg/kg clarithromycin 
i.p., or 0.9% w/v saline vehicle was administered, the next day either 50mg/kg clarithromycin 
i.p. or vehicle was followed by either 0.125mg/kg ultrapure LPS from E. coli K12 (Invivogen) 
i.p. or 0.9% w/v saline vehicle. Animals were culled 90 minutes after LPS/vehicle 
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administration; small intestinal mucosal scrapes were prepared in RIPA buffer with protease 
inhibitors (Sigma, Gillingham, UK). NF-κB p65 DNA binding was quantified using a TransAM 
DNA-binding ELISA (ActiveMotif, La Hulpe, Belgium). 
Dextran sulphate sodium-induced colitis 
Groups of adult (8-10-week-old) male C57BL/6 mice were administered either 10 mg/kg 
clarithromycin, or vehicle by orogastric gavage daily for four days. Following a washout 
period, animals received 2.5% DSS in drinking water, for five days. Animals recovered for a 
further three days. From the start of DSS treatment to termination of the experiment either 
10 mg/kg clarithromycin or normal saline vehicle was administered by daily orogastric gavage. 
Tissue samples were harvested and prepared for histological analysis, including quantitative 
histology, as previously described(Williams et al., 2016). 
Statistical analysis of laboratory work 
Statistical analyses were performed using GraphPad Prism v.7.0 software. Specific statistical 
tests are annotated in the text and figure legends. Reported p-values are two-tailed. 
Normality testing was performed with the D'Agostino & Pearson test. 
Results: 
To predict drugs that may influence disrupted NF-κB signalling in IBD, a drug-discovery 
strategy combining data from multiple sources (archived ChIP-seq analyses; natural language 
text-mining of published abstracts; data from IBD GWAS analyses; and known IBD biomarkers 
and drug targets curated in the HumanPSD database) was developed (Figure 1).  
Developing an enhanced NF-κB signalling network 
Signalling molecules comprising (transcription) regulatory feedback loops present promising 
drug targets because they can influence the dynamics of a signalling pathway of interest, 
including the TNF-alpha/NF-κB pathway. To augment existing knowledge about NF-κB 
signalling, we developed an analysis workflow to identify genes encoding potential 
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components of transcription regulatory feedback loops combining known NF-κB-involving 
signalling pathways, ChIP-seq assay based NF-κB/RelA-bound genomic regions from the 
ENCODE project (GEO series GSE31477), and a newly-developed method to find combinations 
of enriched DNA-sequence motifs (Motif Enrichment Analysis by Logistic Regression (MEALR))  
(see supplementary materials for details). Combinations of prioritised motifs tend to coincide 
with transcription factors that are known to cooperate. Our analysis found 24 transcription 
factors that appear to cooperate in NF-κB signalling within the genomic regions reported by 
ENCODE (Table 1) as well as 90 potential NF-κB/RelA-target genes that encode components 
of known pathways. (Table 2). The results were used to annotate the TRANSPATH® database 
of mammalian signal transduction and metabolic pathways. 
Text mining to establish context proteins and genes for up-stream network analyses 
1000 relevant abstracts were retrieved using the MedlineRanker tool(Gijon-Correas et al., 
2014) from the PubMed database using the MeSH terms “Inflammatory bowel diseases” and 
“NF-κB”. Protein-protein interactions were identified in these abstracts using 
PESCADOR(Barbosa-Silva et al., 2011). PESCADOR detects genes, proteins and their 
interactions, and rates them based on co-occurrences in an abstract. 827 interactions 
common for both Homo sapiens and Mus musculus, 2 for Mus musculus alone, and 26 
uniquely for Homo sapiens were extracted (Supplementary Table S1). After querying the 
TRANSPATH® database for known direct interactions, 127 novel co-occurrences of genes or 
proteins in the abstracts analysed. This table of interactions was used to provide context to 
subsequent up-stream network analysis to impute the key regulatory nodes for NF-κB 
signalling in IBD. 
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Identifying master regulators of the NF-κB signalling network 
An upstream search of the various molecular components of NF-κB complex including: NF-
κB1-isoform1, NF-κB1-isoform2, NF-κB2-isoform4, NF-κB2-p100, NF-κB2-p49, RelA-p35, RelA-
p65-delta, RelA-p65-delta2, RelA-p65-isoform1, RelA-p65-isoform4, RelB, c-Rel was 
performed. The network search extended to a maximal radius of 10 steps upstream of the 
NF-κB components and used a false discovery rate (FDR) cut-off of 0.05 and Z-score (reflecting 
how specific each master regulator was) cut-off of 1.0. The list of interacting proteins 
obtained by text-mining was used to provide “Context proteins” for the master-regulator 
acquisition algorithm(Kel et al., 2016). This analysis revealed 325 controlling nodes predicted 
to exert signalling activity for the NF-κB components (Table S2).  
Developing a list of IBD associated genes and potential therapeutic targets 
A list of IBD associated-genes and potential therapeutic targets was established by retrieving 
information from the HumanPSD database including known IBD biomarkers and drug targets, 
and two lists of IBD-related genes from genome-wide association studies, one focused on 
revealing genes of IBD prognosis(Lee et al., 2017), and another on IBD susceptibility(Hasler et 
al., 2017). 159 IBD-targets were identified and summarised with an indication of the source 
of evidence about their relevance to IBD (Table S3).  
Finally, to produce a list of proposed therapeutic targets the list of IBD-targets was intersected 
with the 325 controlling nodes to obtain 62 candidates (defined as IBD key-nodes, Table S4) 
that represent genes predicted to influence IBD associated NF-κB regulation, which had also 
independently been identified as IBD associated genes or potential therapeutic targets. 
Predicting drugs that may influence the IBD key-nodes 
The PASS software package was used to predict drugs which may interact with IBD key-nodes: 
this software predicts the ability of a chemical structure to interact and influence the activity 
of defined molecular targets and biological activities. 
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The 62 key-nodes were translated into 46 PASS activities (Table S5). To identify compounds 
with potential for clinical re-positioning, the Top 200 drugs library was analysed to predict the 
probability that these established, and licenced agents may interfere with each PASS activity. 
A cumulative score was calculated across all 46 PASS activities for each drug. We also required 
that the drugs were predicted to be active against the PASS activity “Transcription factor NF 
κB inhibitor”.  
29 compounds achieved these criteria (Table 3); importantly, this table included several 
corticosteroids already used to treat IBD, supporting the validity of the discovery strategy. 
The highest-ranked drug was a macrolide antibiotic: clarithromycin. This agent is of particular 
interest because macrolides have an established role in treating aseptic inflammatory 
conditions including chronic rhinosinusitis(Oakley et al., 2017) and panbronchiolitis(Lin et al., 
2015) and because clarithromycin has previously been trialled in IBD with divergent 
outcomes(Leiper et al., 2008; Leiper et al., 2000). We, therefore, considered it to be an 
excellent candidate for strategic repurposing and have used clarithromycin as a paradigm 
molecule for the development of a mechanism-led drug validation pathway. 
Clarithromycin suppresses stimulus-induced luciferase activity in primary cell cultures. 
To validate the efficacy of clarithromycin as an inhibitor of NF-κB mediated transcription, 
primary cultures from the hTNF.LucBAC mouse, a transgenic line that expresses firefly 
luciferase under the control of the entire human TNF promoter(Minshawi et al., 2019), were 
used. 
Luciferase activity was triggered by ligand binding to the TNF receptor and pattern recognition 
receptors including TLR4 (lipopolysaccharide), TLR5 (flagellin) and NOD2 (muramyl dipeptide, 
MDP) (Figures 2A-D) in peritoneal macrophages harvested from this mouse. When cells were 
pre-treated for 30 minutes with 10μM or 100μM clarithromycin, a dose-dependent reduction 
in luciferase activity was observed, independent of the stimulus applied. 
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The effect of clarithromycin on NF-κB activation in murine peritoneal macrophages was 
confirmed by isolating peritoneal macrophages from 4 WT mice, and treating them with 
10μM clarithromycin or vehicle before stimulation with 1μg/ml LPS. Cells were fixed, stained 
for phosphorylated-p65 and quantified by flow cytometry. Median fluorescence intensity 
(MFI) increased on stimulation (p=0.03, ANOVA); co-administration of LPS and clarithromycin 
suppressed this response (p=0.008, Figure 2E). 
Small intestinal organoids (enteroids) were established from hTNF.LucBAC mice to determine 
whether clarithromycin could also alter NF-κB responses in gastrointestinal epithelial cell 
cultures. Luciferase activity was detectable in these cultures in response to 100ng/mL TNF 
administration (Figure 3A and B). Luciferase activity was significantly suppressed by pre-
treatment for 30 minutes with either 1μM (p=0.014) or 10μM (p=0.001) clarithromycin 
(Figure 3B and C). 
Clarithromycin suppresses TNF-induced NF-κB(p65) shuttling in enteroids 
To assess whether clarithromycin influenced NF-κB protein shuttling dynamics, enteroid 
cultures from reporter mice expressing p65-DsRedxp/IκBalpha-eGFP were established. This 
mouse expresses human p65-DsRedxp and human IκBalpha-eGFP fusion proteins. We used 
these organoids in live-cell confocal imaging studies to observe the nuclear translocation of 
p65 in real-time. Images were analysed using CellTracker software(Ashall et al., 2009), which 
allows painstaking quantification of nuclear shuttling of fluorescently labelled proteins. 
Administration of 100ng/mL TNF-induced synchronised p65 translocation to the nucleus of 
cells within enteroids with a periodicity of approximately 50 minutes. This was observed as a 
highly damped shuttling response, with a single wave of synchronised nuclear translocation, 
followed by a second wave of partially synchronised translocation, after which further nuclear 
localisation occurred in an apparently stochastic fashion (Figure 4A and B and supplementary 
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video). When cultures were pre-treated with 10µM clarithromycin for 30 minutes, p65-
DsRedxp nuclear translocation was markedly suppressed. 
To quantify these events more precisely the mean area under the curve (AUC) during the first 
oscillatory wave (Figure 4D) was calculated, and demonstrated decreased nuclear intensity of 
p65-DsRed fluorescence in clarithromycin pre-treated enteroids (p=0.005). The time to peak 
nuclear fluorescence after 100ng/mL TNF administration was also quantified (figure 4E). In 
DMSO vehicle-treated cells, peak fluorescence occurred at a median time of 47.2 (IQR 41.0-
47.2) minutes. This was not significantly different for clarithromycin treated enteroids, but 
there was significantly more cell-to-cell variability observed in clarithromycin treated than 
vehicle-treated cells (p<0.0001, figure 4E). To assess synchronisation of nuclear translocation,  
the time between peak fluorescence and median time for peak nuclear fluorescence was 
calculated for each cell (Figure 4F). This confirmed an 8-fold greater variation in timing for 
peak nuclear fluorescence in CLA treated enteroids compared to controls (p<0.0001), 
confirming that the synchronisation of p65 nuclear translocation was lost following exposure 
to CLA.). 
Clarithromycin suppresses LPS-induced NF-κB (p65) DNA binding in-vivo 
To determine whether the effects of clarithromycin on stimulus-induced NF-κB activity 
observed in-vitro also occurred in-vivo, 0.125mg/kg LPS was administered to groups of six 
C57BL/6 male mice by intraperitoneal injection, either with or without clarithromycin co-
administration. This stimulus induces small intestinal epithelial cell shedding, regulated by 
both NF-κB1 and NF-κB2 signalling pathways(Williams et al., 2013). 
LPS administration induced a 2-fold increase in p65 DNA binding, compared to saline vehicle 
control (p<0.001, 1-way ANOVA and Dunnett’s posthoc test); pre-treatment with 
clarithromycin suppressed this effect by approximately 51% (p=0.007, Figure 5A). 
Clarithromycin suppresses DSS-induced colitis 
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To determine whether clarithromycin affected murine colitis in-vivo, clarithromycin or vehicle 
were administered to mice receiving DSS to induce colitis. Animals received clarithromycin or 
vehicle daily for four days by oro-gastric gavage, after a four-day washout period 2.5% w/v 
DSS in drinking water ad-libitum was commenced for five days, followed by recovery for a 
further three days.  
Mice co-administered DSS and clarithromycin lost significantly less weight than other groups 
(p=0.039, 1-way ANOVA and Dunnett’s posthoc test, Figures 5B and 5C) and had lower 
compound histology scores (p=0.004, Figures 5D and 5F) and a higher number of surviving 
colonic crypts than mice treated with vehicle (p=0.017, Figure 5E); this suggests that 
clarithromycin at least partially ameliorates this model of colitis. 
Clarithromycin suppresses TNF-induced NF-κB (p65) nuclear localisation in human enteroids 
To determine whether the effects identified in murine primary culture and in-vivo 
experiments were also relevant to humans, passaged human ileal organoids from individuals 
with no evidence of IBD were pre-treated with 10µM clarithromycin or DMSO vehicle for 30 
min before stimulation with 100ng/ml TNF. Paraformaldehyde fixed cultures were 
immunostained for p65, and the percentage of cells expressing nuclear-localised p65 was 
quantified. In untreated human enteroids, 0.6% (SEM 0.37) of cells demonstrated p65 nuclear 
localisation, administration of TNF induced a 57-fold increase in cells expressing nuclear p65 
(33%, +/- 3.2 SEM, p<0.0001, 1-way ANOVA and Dunnett’s posthoc test, N=6 per group). Pre-
treatment with clarithromycin suppressed TNF-induced nuclear localisation of p65 to a level 
comparable with DMSO vehicle-treated enteroids. (1%, +/- 0.36 SEM, p<0.0001, Figure 6). 
Discussion: 
This article demonstrates that the macrolide antibiotic clarithromycin is a modifier of NF-κB 
signalling in the gastrointestinal tract. Identification of clarithromycin, using an in-silico screen 
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of licensed drugs, demonstrates how novel bioinformatics can be used to progress drug-
repurposing, a strategy that has the potential to reduce the cost of future drug development.  
The SysmedIBD consortium integrated diverse skill sets to develop this approach which could 
be applied in different ways in the future. An identical bioinformatic analysis could be used to 
screen panels of small molecules to identify novel therapeutics for IBD. Similarly, the system 
could be adapted for use in other contexts where NF-κB signalling is of paramount importance 
or refocussed onto different signalling networks. 
Our list of drugs predicted to influence IBD outcomes included several drugs in routine use 
for IBD, most prominently the corticosteroids, which are used to treat acute relapses of 
inflammatory bowel disease(Truelove and Witts, 1955; Turner et al., 2007). The analysis also 
identified sex hormones including medroxyprogesterone and estradiol which have been 
shown to modulate colitis(Armstrong et al., 2017), and colitis-associated adenoma 
development in vivo(Son et al., 2018); and non-steroidal anti-inflammatory drugs, which, in 
clinical practice, are identified as agents that exacerbate IBD(Long et al., 2016). The harmful 
effects of NSAIDs result from inhibition of constitutively expressed COX-1 in the 
gastrointestinal epithelium, causing epithelial damage and ulceration; inhibition of COX-2, 
which is upregulated at sites of inflammation is a well-established anti-inflammatory 
mechanism, which influences NF-κB signalling. The drug discovery approach deliberately 
included a bias for agents that alter NF-κB signalling; it is likely that NSAIDs have been selected 
because of this bias.  
These observations demonstrate the importance of interdisciplinary working. The in-silico 
drug discovery model is a powerful tool to identify drugs that may be repurposed, but 
decisions about which agents to pursue for further analysis can only be made in the context 
of existing clinical literature. 
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Laboratory evaluation of clarithromycin aimed to demonstrate proof-of-principle that a drug 
identified by in-silico testing would demonstrate the predicted mechanism of action, and 
show efficacy in-vivo.  
Our strategy has potential for development into a higher throughput compound screening 
system: for example, the hTNF.LucBAC macrophage assay can be performed in a 96-well plate 
format, and peritoneal macrophages are abundant, simple to extract and highly sensitive to 
stimulus. Reporter enteroids generated from hTNF.LucBAC mice allowed us to validate the 
findings seen in peritoneal macrophages in a relevant, untransformed epithelial model using 
comparable technology, but are unlikely to be amenable to high-throughput assay 
development due to the challenges (and cost) of maintaining a 3D culture in a small well in a 
culture plate. 
The visualisation of p65.DsRed translocation between the nucleus and cytoplasm in enteric 
organoids is technically challenging, and not immediately scalable. One of the challenges that 
we persistently encountered was fluctuating fluorescence prior to stimulation with TNF, 
despite efforts to rest the cells prior to imaging. Unlike a monoculture of immune cells 
enteroids are a complex system with several cell types represented within the organoid 
structure. Whether this is due to paracrine secretion between different cells within the 
organoid structure, or is a factor related to organoid culture conditions is not possible to 
dissect currently. Our assays also demonstrated fundamental differences in NF-κB signalling 
dynamics compared to cancer cell lines(Harper et al., 2018; Nelson et al., 2004), with TNF-
induced p65 oscillations being heavily damped in organoids. This observation demonstrates 
the value of  untransformed primary culture; the mechanisms underlying these differences 
will be subject to further investigation.   
The observation that intestinal NF-κB signalling is altered by clarithromycin in-vivo is in 
keeping with earlier work using cancer cell lines(Peng et al., 2014), but it is the first 
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demonstration that macrolides alter this signalling pathway in either untransformed 
enteroids or gastrointestinal mucosae in vivo. 
Previous studies demonstrated that a non-antibiotic macrolide, CSY0073, influenced acute 
DSS colitis in C57BL/6 mice(Mencarelli et al., 2011), but clarithromycin had not been studied. 
Our murine experiments were complicated by the antibiotic effects of Clarithromycin. Murine 
models of colitis are known to vary dependent on animal house conditions and host enteric 
microbiota. Several strategies could have been adopted to help differentiate antibiotic and 
anti-inflammatory effects of clarithromycin, all of which arte flawed. Germ free mice and 
gnotobiotic mice have been used to impute impacts of gut microbiota in inflammatory bowel 
disease models, but they are flawed as immune systems development is divergent in germ 
free mice. Broad spectrum antibiotics have been usedin an attempt to eradicate commensal 
enteric bacteris, but no antibiotic combination will effectively achieve this goal, and its effect 
on the mycobiome and virome would be unquantifiable.  
We preferred to adopt a consistent approach that was based on pre-exposure to the 
clarithromycin. The intention of this approach was to build evidence for the antibiotic effect 
of CLA by examining the impact of pre-treatment with CLA, and comparing to the anti-
inflammatory effects of sustained CLA treatment. In the LPS administration experiment the 
timepoinrts are extremely short, therefore an antibiotic effect within the experimental period 
is highly unlikely to explain differences between CLA pretreated animals and animals 
administered CLA immediately before LPS. The antibiotic effect is a greater concern in the DSS 
experiment, but the inclusion of  data from relevant control animals has allowed us to unpick 
the anti-inflammatory effect. Intriguingly the histological damage in mice pretreated with CLA 
was worse than that seen in the vehicle control mice, suggesting that the antibiotic effect in 
this model may, if anything, have the opposite effect to sustained CLA treatment. 
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The in-vivo studies rely on studying the whole organism and it was not feasible to separate 
epithelial and immune compartments during this study, this was one of the prime motivations 
for studying immune and epithelial models in-vitro 
Our final validation was to characterise whether clarithromycin influenced human epithelial 
NF-κB signalling. We investigated this using a HeLa reporter cell-line model, which is fast, 
inexpensive, commercially available and could be adapted as a high throughput screening test 
(figure S2), but it is inferior to the hTNF.LucBAC mouse primary culture models as NF-κB 
signalling is dysregulated in many cancer cell lines. By generating human enteroids, 
clarithromycin’s effect on a primary, untransformed human epithelial cell culture could be 
assessed. Unfortunately, the assay used for NF-κB activation in this model was necessarily less 
specific, but the results supported those obtained with other assays. 
It was serendipitous that the highest-ranked agent identified for repurposing was a drug that 
had already been trialled in IBD. Importantly the outcomes of previous trials of clarithromycin 
in IBD have been heterogeneous, suggesting that there may be context-dependent factors 
that determine whether clarithromycin is useful in a group of patients.  
Four published papers, and a conference abstract have reported the effect of clarithromycin 
in IBD: they all focussed on Crohn’s disease and were predicated on an antibiotic effect of 
clarithromycin, either targeting intra-macrophage killing of E. coli(Leiper et al., 2008; Leiper 
et al., 2000) or attempting to eradicate Mycobacterium avium paratuberculosis(Goodgame et 
al., 2001; Graham et al., 1995; Selby et al., 2007).  
Several factors may explain the discordant outcomes:  
In all studies of clarithromycin’s effect on IBD, patient inclusion was based on clinical 
definitions of active IBD and response assessed by clinical outcome measures. These 
measures lack objectivity and would not be acceptable endpoints or selection criteria for a 
current study.  
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Selby(Selby et al., 2007) and Goodgame(Goodgame et al., 2001).   assessed the long-term 
effect of bacterial eradication; any anti-inflammatory effect would have been lost during the 
prolonged follow-up period before the primary endpoint was assessed.  
Leiper et al examined an earlier timepoint when anti-inflammatory effects, could have been 
observed, but were not the focus of the study. Two separate cohorts of patients with clinically 
active Crohn’s disease were recruited from a single centre; in the first study clarithromycin 
appeared to improve patient outcomes, but the same was not observed during the second 
study.  
At the time, the divergent outcomes were explained by the small size of the initial study, and 
the relatively soft criteria for inclusion of patients with active inflammatory bowel disease. 
These explanations may still be valid, but an alternative hypothesis is that a sub-group of 
patients with active disease may respond to clarithromycin. One of the motivations for 
investigating existing drugs during this study was specifically to identify agents that have 
equivocal evidence based on traditional trials but that have evidence for an untested 
mechanism of action. 
The current study confirms that in addition to its antibiotic effect, clarithromycin has anti-
inflammatory properties, which are relevant to gastrointestinal epithelia. Further carefully 
designed clinical studies will be needed to test the anti-inflammatory effects of treatment 
with clarithromycin.  
Earlier discordant trial results raise questions about trial design and patient selection. In the 
current era of precision medicine, it is important that patients are carefully selected for 
treatments, and that agents with previous dichotomous clinical trial results are revisited. To 
effectively review drugs for precision use, their mechanisms of action need to be understood. 
This study has helped us to understand how clarithromycin affects NF-κB signalling dynamics, 
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and we hypothesise that it should be possible to select a group of clarithromycin-responsive 
patients based on their NF-κB signalling status. 
Our consortium has recently shown that patients with IBD cluster into several different 
cohorts based on a dynamic measure of NF-κB responses in peripheral blood monocyte 
derived macrophages(Papoutsopoulou et al., 2019). We hypothesise that, by using this new 
measure of NF-κB activity, it will be possible to identify IBD patients most likely to respond to 
NF-κB targeted therapy in the form of clarithromycin, and thereby leverage a precision 
medicine trial. 
In conclusion, our findings strongly suggest that clarithromycin may be a viable, anti-
inflammatory therapeutic agent for IBD. In order to progress to a personalised medicine trial 
of clarithromycin in IBD a partner diagnostic test which can demonstrate altered NF-κB 
dynamics in patients’ peripheral blood monocyte-derived macrophages is under 
development(Papoutsopoulou et al., 2019), once established this will be used to inform a 
personalised drug repurposing trial for clarithromycin in IBD. 
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Figure 1: Schematic representation of the bioinformatic approach to identifying drugs with 
the potential to modulae IBD and NF-κB signalling. 
Figure 2. A-D: Luciferase activation curves for peritoneal macrophages extracted from 
HTNF.LucBAC mice stimulated with 10ng/mL LPS (A), 40 ng/mL TNF (B), 10μg/mL MDP (C) or 
500ng/ml flagellin (D). Solid lines indicate cells response of pre-treated with drug vehicle 
(DMSO), dashed and dotted lines responses generated from cells pre-treated with 10μM or 
100 μM clarithromycin, respectively. E: Median fluorescence intensity for anti-phopsho-p65 
antibody stained peritoneal macrophages from C57BL/6 mice either unstimulated or 
stimulated with LPS and pre-treated with 10μM clarithromycin or DMSO vehicle. N=4 mice. 
Statistically significant differences tested by 1-way ANOVA and Dunnett’s post hoc test. 
Figure 3: Representative luciferase activation curves for enteroids derived from HTNF.LucBAC 
mice either unstimulated (A) or stimulated with 100ng/mL TNF (B), and without pre-
treatment (solid line) or 30 min pre-treatment with, DMSO vehicle (dashed line), 1μM 
clarithromycin (dotted line) or 10μM clarithromycin (dotted and dashed line). C: Area under 
the curve (AUC) calculations for the same experiment. N=3. Statistically significant differences 
tested by 2-way ANOVA and Dunnett’s posthoc test. 
Figure 4 A: Representative images of bright field (upper panels) and red channel (lower 
panels) images of dynamic, live-cell imaging studies of enteroids derived from p65-DsRedxp/ 
IκBalpha-eGFP mice, either untreated, treated with clarithromycin alone, treated with 
100ng/mL TNF alone, or pre-treated with 10μM clarithromycin and subsequently stimulated 
with TNF. B and C: Relative nuclear red fluorescence curves for individual cells (grey lines), 
mean (solid red line) and 1 SD above and below the mean (dashed red lines) over time. Cells 
pre-treated with DMSO vehicle (B) or clarithromycin (C) at time -35 min and stimulated with 
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TNF at time 0 min. D: Area under the curve calculations for individual cells between time 0 
and time 90 min for panels B and C. Statistically significant differences tested by Mann-
Whitney U test. E: Time to peak fluorescence, post-TNF stimulation for individual cells, 
statistically significant differences tested by Mann-Whitney U test. F: Distance of individual 
cells peak fluorescence from the median value, statistically significant differences tested by 
Mann-Whitney U test. N=88 vehicle pre-treated, 62 clarithromycin pre-treated cells for panels 
D-F, lines represent median and IQR for these panels. 
Figure 5A: Relative p65 DNA binding activity in whole-cell lysates from proximal small 
intestine of C57BL/6 mice pretreated for three days with 50mg/kg clarithromycin or saline 
vehicle, and subsequently injected i.p. with 0.125mg/kg LPS or vehicle. N=5-6. B-F: Effect of 
clarithromycin on outcomes of DSS colitis in C57BL/6 mice. B: Weight loss plotted over time. 
C: Area under the curve analysis of weight loss. D: Histology severity scores. E: Number of 
surviving crypts per colonic circumference. F: Representative photomicrographs of the 
colonic mucosa of DSS treated mice co-treated with saline vehicle or 10mg/kg clarithromycin 
by oro-gastric gavage. N=9-10. Statistically significant differences tested by 1-way ANOVA and 
Dunnett’s post hoc test in all panels. 
Figure 6A: Representative photomicrographs of human ileal enteroids either unstimulated or 
stimulated with 100ng/ml TNF, and either co-administered DMSO vehicle or 10µM 
clarithromycin and immunostained for total p65. B: Quantification of nuclear p65 staining of 















































ENSG00000005339 CREBBP 1 
ENSG00000015475 BID 2 
ENSG00000030110 BAK1 1 
ENSG00000034152 MAP2K3 1 
ENSG00000049759 NEDD4L 3 
ENSG00000051382 PIK3CB 1 
ENSG00000051523 CYBA 1 
ENSG00000069399 BCL3 2 
ENSG00000077150 NFKB2 2 
ENSG00000081059 TCF7 3 
ENSG00000082701 GSK3B 1 
ENSG00000083799 CYLD 1 
ENSG00000084676 NCOA1 2 
ENSG00000099341 PSMD8 1 
ENSG00000100324 TAB1 2 
ENSG00000100365 NCF4 2 
ENSG00000100387 RBX1 1 
ENSG00000101849 TBL1X 1 
ENSG00000102871 TRADD 1 
ENSG00000104365 IKBKB 2 
ENSG00000104825 NFKBIB 1 
ENSG00000104856 RELB 2 
ENSG00000105647 PIK3R2 1 
ENSG00000107263 RAPGEF1 3 
ENSG00000109320 NFKB1 2 
ENSG00000109332 UBE2D3 2 
ENSG00000110330 BIRC2 1 
ENSG00000111186 WNT5B 1 
ENSG00000112062 MAPK14 1 
ENSG00000115415 STAT1 2 
ENSG00000116473 RAP1A 2 
ENSG00000116701 NCF2 1 
ENSG00000118260 CREB1 1 
ENSG00000118503 TNFAIP3 2 
ENSG00000119487 MAPKAP1 3 
ENSG00000121879 PIK3CA 1 
ENSG00000124486 USP9X 1 
ENSG00000125084 WNT1 1 
ENSG00000125347 IRF1 1 
ENSG00000127191 TRAF2 2 
ENSG00000127666 TICAM1 1 
ENSG00000131323 TRAF3 5 
ENSG00000131508 UBE2D2 1 
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ENSG00000134070 IRAK2 2 
ENSG00000136689 IL1RN 1 
ENSG00000136807 CDK9 1 
ENSG00000136810 TXN 1 
ENSG00000137275 RIPK1 2 
ENSG00000141510 TP53 1 
ENSG00000142453 CARM1 1 
ENSG00000144802 NFKBIZ 2 
ENSG00000145675 PIK3R1 1 
ENSG00000146232 NFKBIE 1 
ENSG00000148053 NTRK2 1 
ENSG00000148737 TCF7L2 1 
ENSG00000150991 UBC 1 
ENSG00000154589 LY96 1 
ENSG00000157764 BRAF 1 
ENSG00000161011 SQSTM1 1 
ENSG00000162736 NCSTN 1 
ENSG00000162924 REL 2 
ENSG00000163932 PRKCD 3 
ENSG00000164327 RICTOR 1 
ENSG00000166167 BTRC 1 
ENSG00000168036 CTNNB1 1 
ENSG00000169967 MAP3K2 1 
ENSG00000170315 UBB 1 
ENSG00000171552 BCL2L1 2 
ENSG00000171608 PIK3CD 2 
ENSG00000172936 MYD88 1 
ENSG00000173039 RELA 1 
ENSG00000174130 TLR6 1 
ENSG00000177606 JUN 1 
ENSG00000183207 RUVBL2 1 
ENSG00000185338 SOCS1 1 
ENSG00000185507 IRF7 1 
ENSG00000185627 PSMD13 1 
ENSG00000186197 EDARADD 1 
ENSG00000196470 SIAH1 1 
ENSG00000197153 HIST1H3J 2 
ENSG00000197409 HIST1H3D 3 
ENSG00000197442 MAP3K5 3 
ENSG00000198400 NTRK1 1 
ENSG00000205155 PSENEN 2 
ENSG00000213281 NRAS 1 
ENSG00000226979 LTA 4 
ENSG00000227507 LTB 3 
ENSG00000232810 TNF 4 
ENSG00000243414 TICAM2 2 
ENSG00000263528 IKBKE 3 
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 Supplementary figures 
Supplementary figure S1: Schematic of the transcriptional feedback loops sought by our 
analysis. Upon activation through upstream signalling cascades the transcriptional regulator 
NF-kappa-B/RelA (and cooperating transcription factors) control expression of target genes 
which may themselves play a role in signalling cascades regulating the activity of NF-kappa-
B/RelA thereby establishing a positive or negative feedback loop depending on whether NF-
kappa-B/RelA enhances or interferes with the transcription of respective target genes. B: More 
detailed illustration of identified feedback loops. Using consensus NF-kappa-B/RelA binding 
sites collected from 10 ChIP-seq experiments we analysed their genomic locations with respect 
to nearby potential target genes which were known components of relevant pathways and/or 
transcription factors whose motifs played a role for target sequence recognition as inferred by 
MEALR. Details of the compiled and analysed data are exemplified for pathway target genes 
TNF, LTA and LTB on chromosome 6 and for the cooperating transcription factor JUN on 
chromosome 1. The consensus peak density presentation was calculated using the CMplot 
package. The detailed views of genomic regions were created using the genome browser of 
the geneXplain platform. 
Supplementary Video: Representative timelapse confocal video of red channel images of dynamic, 
live-cell imaging studies of enteroids derived from p65-DsRedxp/ IκBalpha-eGFP mice, either treated 
with 100ng/mL TNF alone, or pre-treated with 10μM clarithromycin and subsequently stimulated with 
TNF. 
Supplementary Figure S2:  Relative luciferase activity in unstimulated HeLa cells treated with DMSO 
vehicle (open bar), 1uM (hatched bar) or 10uM (solid bar) clarithromycin. B: Relative luciferase activity 
in TNF stimulated HeLa cells treated with DMSO vehicle, 1uM or 10uM CLA. * denotes p<.05, 
****p<.0001, by 2-way ANOVA and Dunnett’s posthoc test. 
Supplementary Table S1: NF-κB co-operating transcription factors identified by MEALR 
Supplementary Table S2: Interactions between genes and or proteins identified by text mining 
algorithm 
Supplementary Table S3: Controlling node genes that may regulate signalling activity on the NF-κB 
network 
Supplementary Table S4: IBD target genes, with source of data 
Supplementary Table S5: List of IBD key-nodes, potential therapeutic targets for IBD 





















































































Table S2: Interactions between genes and/or proteins identified by text mining algorithm
Gene Symbol 1 Gene Symbol 2 Type of interaction Mouse / Human 
Abl c-Jun Process Human
AKT-1 ASK1 Process Human
ASK1 MKK6 Process Human
Caspase-8 parkin Process Human
ERK2 TAB1 Process Human
IKK NF-kappaB1 Process Human
JNK1 JNK1alpha1 Process Human
JNK1 JNK2 Process Human
JNK1alpha1 TAB1 Process Human
JNK2 MKK7 Process Human
MEK1 MEKK1 Process Human
MEKK1 STAT3 Process Human
MKK6 TRAF2 Process Human
MSK1 p38alpha Process Human
MyD88 TLR9 Process Human
NF-kappaB1 NF-kappaB1-p50 Association Human
NF-kappaB1 p50 Association Human
NF-kappaB1 RelA-p65 Association Human
NF-kappaB1-p50 p50 Association Human
NF-kappaB1-p50 RelA-p65 Association Human
Nod2 TRAF2 Association Human
Nod2 ubiquitin Association Human
parkin ubiquitin Association Human
TAK1 TAK1a Association Human
TAK1a TRAF2 Association Human
TAK1a ubiquitin Association Human
JIP1 JNK1 Process Mouse
PKCzeta proCaspase-3 Process Mouse
26S proteasome IkappaB-alpha Process Both
26S proteasome p105 Dissociation Both
26S proteasome p50 Dissociation Both
26S proteasome p50 Process Both
26S proteasome RelA-p65 Process Both
26S proteasome ubiquitin Dissociation Both
26S proteasome ubiquitin Process Both
A20 IKK Process Both
A20 IKK-beta Process Both
A20 RIP Dissociation Both
A20 TRADD Dissociation Both
A20 TRAF2 Dissociation Both
A20 ubiquitin Dissociation Both
Abl Caspase-8 Dissociation Both
Abl IkappaB-alpha Process Both
acetyl-CoA carm1 Process Both
acetyl-CoA CBP Process Both
acetyl-CoA CoA Process Both
acetyl-CoA histone H3 Process Both
acetyl-CoA p50 Process Both
acetyl-CoA RelA-p65 Process Both
acetyl-CoA SRC-1 Process Both
ASK1 MKK4 Process Both
ASK1 TNF-alpha Process Both
ASK1 TNFR1 Process Both
ASK1 TRADD Process Both
ASK1 TRAF2 Process Both
ASK1 Trx1 Association Both
ASK1 Trx1 Dissociation Both
Bak Bid Association Both
Bak Bid Process Both
Bak Cytochrome C Process Both
Bak tBid Association Both
Bak tBid Process Both
Bid Caspase-8 Dissociation Both
Bid Cytochrome C Process Both
Bid tBid Association Both
Bid tBid Dissociation Both
Bid tBid Process Both
carm1 CBP Association Both
carm1 CBP Process Both
carm1 Cdk9 Association Both
carm1 Cdk9 Process Both
carm1 CoA Process Both
carm1 cyclinT1 Association Both
carm1 cyclinT1 Process Both
carm1 histone H3 Process Both
carm1 IL8 Process Both
carm1 p50 Association Both
carm1 p50 Process Both
carm1 RelA-p65 Association Both
carm1 RelA-p65 Process Both
carm1 S-adenosylhomocysteine Process Both
carm1 S-adenosylmethionine Process Both
carm1 SRC-1 Association Both
carm1 SRC-1 Process Both
Caspase-2 CRADD Association Both
Caspase-2 CRADD Dissociation Both
Caspase-2 proCaspase-2 Association Both
Caspase-2 proCaspase-2 Dissociation Both
Caspase-2 RIP Association Both
Caspase-2 RIP Dissociation Both
Caspase-2 TNF-alpha Association Both
Caspase-2 TNF-alpha Dissociation Both
Caspase-2 TNFR1 Association Both
Caspase-2 TNFR1 Dissociation Both
Caspase-2 TRADD Association Both
Caspase-2 TRADD Dissociation Both
Caspase-8 FADD Association Both
Caspase-8 FADD Dissociation Both
Caspase-8 proCaspase-3 Process Both
Caspase-8 tBid Dissociation Both
Caspase-8 TNF-alpha Association Both
Caspase-8 TNF-alpha Dissociation Both
Caspase-8 TNFR1 Association Both
Caspase-8 TNFR1 Dissociation Both
Caspase-8 TRADD Association Both
Caspase-8 TRADD Dissociation Both
CBP Cdk9 Association Both
CBP Cdk9 Process Both
CBP CoA Process Both
CBP cyclinT1 Association Both
CBP cyclinT1 Process Both
CBP histone H3 Process Both
CBP IKK Process Both
CBP IKK-alpha Process Both
CBP IL8 Process Both
CBP p50 Association Both
CBP p50 Process Both
CBP RelA-p65 Association Both
CBP RelA-p65 Process Both
CBP S-adenosylhomocysteine Process Both
CBP S-adenosylmethionine Process Both
CBP SRC-1 Association Both
CBP SRC-1 Process Both
CD14 IRAK-1 Association Both
CD14 IRAK-1 Process Both
CD14 lbp Association Both
CD14 lbp Process Both
CD14 LPS Association Both
CD14 LPS Process Both
CD14 MD-2 Association Both
CD14 MD-2 Process Both
CD14 MEKK1 Association Both
CD14 MyD88 Association Both
CD14 MyD88 Process Both
CD14 SITPEC Association Both
CD14 tab2 Process Both
CD14 TLR4 Association Both
CD14 TLR4 Process Both
CD14 traf6 Association Both
CD14 traf6 Process Both
Cdc34 Cul-1 Process Both
Cdc34 IkappaB-alpha Process Both
Cdc34 p50 Process Both
Cdc34 RelA-p65 Process Both
Cdc34 Ubc5 Process Both
Cdc34 ubiquitin Process Both
Cdk9 cyclinT1 Association Both
Cdk9 cyclinT1 Process Both
Cdk9 IL8 Process Both
Cdk9 p50 Association Both
Cdk9 p50 Process Both
Cdk9 RelA-p65 Association Both
Cdk9 RelA-p65 Process Both
Cdk9 SRC-1 Association Both
Cdk9 SRC-1 Process Both
ceramide N-SMase Process Both
ceramide SM Process Both
c-Jun JNK1 Process Both
c-Jun JNK2 Process Both
c-Jun MKK7 Process Both
CoA histone H3 Process Both
CoA p50 Process Both
CoA RelA-p65 Process Both
CoA SRC-1 Process Both
CRADD proCaspase-2 Association Both
CRADD proCaspase-2 Dissociation Both
CRADD RIP Association Both
CRADD RIP Dissociation Both
CRADD TNF-alpha Association Both
CRADD TNF-alpha Dissociation Both
CRADD TNFR1 Association Both
CRADD TNFR1 Dissociation Both
CRADD TRADD Association Both
CRADD TRADD Dissociation Both
Cul-1 IkappaB-alpha Association Both
Cul-1 IkappaB-alpha Process Both
Cul-1 p105 Association Both
Cul-1 p50 Association Both
Cul-1 p50 Process Both
Cul-1 RelA-p65 Association Both
Cul-1 RelA-p65 Process Both
Cul-1 Ubc5 Process Both
Cul-1 Ubc5C Process Both
Cul-1 ubiquitin Association Both
Cul-1 ubiquitin Process Both
cyclinT1 IL8 Process Both
cyclinT1 p50 Association Both
cyclinT1 p50 Process Both
cyclinT1 RelA-p65 Association Both
cyclinT1 RelA-p65 Process Both
cyclinT1 SRC-1 Association Both
cyclinT1 SRC-1 Process Both
Cytochrome C tBid Process Both
E1 tab2 Process Both
E1 traf6 Process Both
E1 ubiquitin Process Both
EAC IKK Process Both
EAC IKK-gamma Process Both
EAC RIP Association Both
EAC RIP Dissociation Both
EAC TNF-alpha Association Both
EAC TNF-alpha Dissociation Both
EAC TNFR1 Association Both
EAC TNFR1 Dissociation Both
EAC TRADD Association Both
EAC TRADD Dissociation Both
EAC TRAF2 Association Both
EAC TRAF2 Dissociation Both
EAC ubiquitin Dissociation Both
FADD TNF-alpha Association Both
FADD TNF-alpha Dissociation Both
FADD TNFR1 Association Both
FADD TNFR1 Dissociation Both
FADD TRADD Association Both
FADD TRADD Dissociation Both
FAN N-SMase Process Both
FAN RACK1 Association Both
FAN RACK1 Process Both
FAN SM Process Both
FAN TNF-alpha Association Both
FAN TNF-alpha Process Both
FAN TNFR1 Association Both
FAN TNFR1 Process Both
histone H3 p50 Process Both
histone H3 RelA-p65 Process Both
histone H3 S-adenosylhomocysteine Process Both
histone H3 S-adenosylmethionine Process Both
histone H3 SRC-1 Process Both
ICAM1 miR-221/222/222ab/1928 Process Both
ICAM1 p50 Process Both
ICAM1 RelA-p65 Process Both
IkappaB-alpha IKK Process Both
IkappaB-alpha IKK-alpha Process Both
IkappaB-alpha IKK-beta Process Both
IkappaB-alpha IKK-gamma Process Both
IkappaB-alpha p50 Association Both
IkappaB-alpha p50 Dissociation Both
IkappaB-alpha p50 Process Both
IkappaB-alpha RelA-p65 Association Both
IkappaB-alpha RelA-p65 Dissociation Both
IkappaB-alpha RelA-p65 Process Both
IkappaB-alpha Ubc5 Process Both
IkappaB-alpha Ubc5C Process Both
IkappaB-alpha ubiquitin Process Both
IKK IKK-alpha Association Both
IKK IKK-alpha Dissociation Both
IKK IKK-alpha Process Both
IKK IKK-beta Association Both
IKK IKK-beta Dissociation Both
IKK IKK-beta Process Both
IKK IKK-gamma Association Both
IKK IKK-gamma Dissociation Both
IKK IKK-gamma Process Both
IKK MEKK1 Process Both
IKK NIK Association Both
IKK NIK Dissociation Both
IKK NIK Process Both
IKK p105 Process Both
IKK p50 Process Both
IKK p62 Association Both
IKK p62 Dissociation Both
IKK p62 Process Both
IKK PKCzeta Association Both
IKK PKCzeta Dissociation Both
IKK PKCzeta Process Both
IKK RelA-p65 Process Both
IKK RIP Association Both
IKK RIP Dissociation Both
IKK RIP Process Both
IKK SITPEC Process Both
IKK TAB1 Process Both
IKK tab2 Association Both
IKK tab2 Dissociation Both
IKK tab2 Process Both
IKK tab3 Association Both
IKK tab3 Dissociation Both
IKK tab3 Process Both
IKK TAK1 Association Both
IKK TAK1 Dissociation Both
IKK TAK1 Process Both
IKK TNF-alpha Association Both
IKK TNF-alpha Dissociation Both
IKK TNF-alpha Process Both
IKK TNFR1 Association Both
IKK TNFR1 Dissociation Both
IKK TNFR1 Process Both
IKK TRADD Association Both
IKK TRADD Dissociation Both
IKK TRADD Process Both
IKK TRAF2 Association Both
IKK TRAF2 Dissociation Both
IKK TRAF2 Process Both
IKK traf6 Process Both
IKK-alpha IKK-beta Association Both
IKK-alpha IKK-beta Dissociation Both
IKK-alpha IKK-beta Process Both
IKK-alpha IKK-gamma Association Both
IKK-alpha IKK-gamma Dissociation Both
IKK-alpha IKK-gamma Process Both
IKK-alpha MEKK1 Process Both
IKK-alpha NIK Association Both
IKK-alpha NIK Dissociation Both
IKK-alpha NIK Process Both
IKK-alpha p50 Process Both
IKK-alpha p62 Association Both
IKK-alpha p62 Dissociation Both
IKK-alpha p62 Process Both
IKK-alpha PKCzeta Association Both
IKK-alpha PKCzeta Dissociation Both
IKK-alpha PKCzeta Process Both
IKK-alpha RelA-p65 Process Both
IKK-alpha RIP Association Both
IKK-alpha RIP Dissociation Both
IKK-alpha RIP Process Both
IKK-alpha SITPEC Process Both
IKK-alpha TAB1 Process Both
IKK-alpha tab2 Association Both
IKK-alpha tab2 Dissociation Both
IKK-alpha tab2 Process Both
IKK-alpha tab3 Association Both
IKK-alpha tab3 Dissociation Both
IKK-alpha tab3 Process Both
IKK-alpha TAK1 Association Both
IKK-alpha TAK1 Dissociation Both
IKK-alpha TAK1 Process Both
IKK-alpha TNF-alpha Association Both
IKK-alpha TNF-alpha Dissociation Both
IKK-alpha TNF-alpha Process Both
IKK-alpha TNFR1 Association Both
IKK-alpha TNFR1 Dissociation Both
IKK-alpha TNFR1 Process Both
IKK-alpha TRADD Association Both
IKK-alpha TRADD Dissociation Both
IKK-alpha TRADD Process Both
IKK-alpha TRAF2 Association Both
IKK-alpha TRAF2 Dissociation Both
IKK-alpha TRAF2 Process Both
IKK-alpha traf6 Process Both
IKK-beta IKK-gamma Association Both
IKK-beta IKK-gamma Dissociation Both
IKK-beta IKK-gamma Process Both
IKK-beta MEKK1 Process Both
IKK-beta NIK Association Both
IKK-beta NIK Dissociation Both
IKK-beta NIK Process Both
IKK-beta p105 Process Both
IKK-beta p50 Process Both
IKK-beta p62 Association Both
IKK-beta p62 Dissociation Both
IKK-beta p62 Process Both
IKK-beta PKCzeta Association Both
IKK-beta PKCzeta Dissociation Both
IKK-beta PKCzeta Process Both
IKK-beta RelA-p65 Process Both
IKK-beta RIP Association Both
IKK-beta RIP Dissociation Both
IKK-beta RIP Process Both
IKK-beta SITPEC Process Both
IKK-beta TAB1 Process Both
IKK-beta tab2 Association Both
IKK-beta tab2 Dissociation Both
IKK-beta tab2 Process Both
IKK-beta tab3 Association Both
IKK-beta tab3 Dissociation Both
IKK-beta tab3 Process Both
IKK-beta TAK1 Association Both
IKK-beta TAK1 Dissociation Both
IKK-beta TAK1 Process Both
IKK-beta TNF-alpha Association Both
IKK-beta TNF-alpha Dissociation Both
IKK-beta TNF-alpha Process Both
IKK-beta TNFR1 Association Both
IKK-beta TNFR1 Dissociation Both
IKK-beta TNFR1 Process Both
IKK-beta TRADD Association Both
IKK-beta TRADD Dissociation Both
IKK-beta TRADD Process Both
IKK-beta TRAF2 Association Both
IKK-beta TRAF2 Dissociation Both
IKK-beta TRAF2 Process Both
IKK-beta traf6 Process Both
IKK-gamma MEKK1 Process Both
IKK-gamma NIK Association Both
IKK-gamma NIK Dissociation Both
IKK-gamma NIK Process Both
IKK-gamma p50 Process Both
IKK-gamma p62 Association Both
IKK-gamma p62 Dissociation Both
IKK-gamma p62 Process Both
IKK-gamma PKCzeta Association Both
IKK-gamma PKCzeta Dissociation Both
IKK-gamma PKCzeta Process Both
IKK-gamma RelA-p65 Process Both
IKK-gamma RIP Association Both
IKK-gamma RIP Dissociation Both
IKK-gamma RIP Process Both
IKK-gamma SITPEC Process Both
IKK-gamma TAB1 Process Both
IKK-gamma tab2 Association Both
IKK-gamma tab2 Dissociation Both
IKK-gamma tab2 Process Both
IKK-gamma tab3 Association Both
IKK-gamma tab3 Dissociation Both
IKK-gamma tab3 Process Both
IKK-gamma TAK1 Association Both
IKK-gamma TAK1 Dissociation Both
IKK-gamma TAK1 Process Both
IKK-gamma TNF-alpha Association Both
IKK-gamma TNF-alpha Dissociation Both
IKK-gamma TNF-alpha Process Both
IKK-gamma TNFR1 Association Both
IKK-gamma TNFR1 Dissociation Both
IKK-gamma TNFR1 Process Both
IKK-gamma TRADD Association Both
IKK-gamma TRADD Dissociation Both
IKK-gamma TRADD Process Both
IKK-gamma TRAF2 Association Both
IKK-gamma TRAF2 Dissociation Both
IKK-gamma TRAF2 Process Both
IKK-gamma traf6 Process Both
IL-10 IL-1RI Process Both
IL-10 IL-1RII Process Both
IL-1beta-p17 IL-1RA Association Both
IL-1beta-p17 IL-1RA Process Both
IL-1beta-p17 IL-1RAcP Association Both
IL-1beta-p17 IL-1RAcP Process Both
IL-1beta-p17 IL-1RI Association Both
IL-1beta-p17 IL-1RI Process Both
IL-1beta-p17 IL-1RII Association Both
IL-1beta-p17 IRAK-1 Association Both
IL-1beta-p17 IRAK-1 Process Both
IL-1beta-p17 IRAK-2 Association Both
IL-1beta-p17 IRAK-2 Process Both
IL-1beta-p17 IRAK-4 Association Both
IL-1beta-p17 IRAK-4 Process Both
IL-1beta-p17 MEKK1 Association Both
IL-1beta-p17 MyD88 Association Both
IL-1beta-p17 MyD88 Process Both
IL-1beta-p17 Pellino1 Process Both
IL-1beta-p17 SITPEC Association Both
IL-1beta-p17 tab2 Process Both
IL-1beta-p17 traf6 Association Both
IL-1beta-p17 traf6 Process Both
IL-1RA IL-1RAcP Association Both
IL-1RA IL-1RAcP Process Both
IL-1RA IL-1RI Association Both
IL-1RA IL-1RI Process Both
IL-1RA IL-1RII Association Both
IL-1RA IRAK-1 Association Both
IL-1RA IRAK-1 Process Both
IL-1RA IRAK-2 Association Both
IL-1RA IRAK-2 Process Both
IL-1RA IRAK-4 Association Both
IL-1RA IRAK-4 Process Both
IL-1RA MEKK1 Association Both
IL-1RA MyD88 Association Both
IL-1RA MyD88 Process Both
IL-1RA Pellino1 Process Both
IL-1RA SITPEC Association Both
IL-1RA tab2 Process Both
IL-1RA traf6 Association Both
IL-1RA traf6 Process Both
IL-1RAcP IL-1RI Association Both
IL-1RAcP IL-1RI Process Both
IL-1RAcP IL-1RII Association Both
IL-1RAcP IRAK-1 Association Both
IL-1RAcP IRAK-1 Process Both
IL-1RAcP IRAK-2 Association Both
IL-1RAcP IRAK-2 Process Both
IL-1RAcP IRAK-4 Association Both
IL-1RAcP IRAK-4 Process Both
IL-1RAcP MEKK1 Association Both
IL-1RAcP MyD88 Association Both
IL-1RAcP MyD88 Process Both
IL-1RAcP Pellino1 Process Both
IL-1RAcP SITPEC Association Both
IL-1RAcP tab2 Process Both
IL-1RAcP traf6 Association Both
IL-1RAcP traf6 Process Both
IL-1RI IL-1RII Association Both
IL-1RI IL-1RII Process Both
IL-1RI IRAK-1 Association Both
IL-1RI IRAK-1 Process Both
IL-1RI IRAK-2 Association Both
IL-1RI IRAK-2 Process Both
IL-1RI IRAK-4 Association Both
IL-1RI IRAK-4 Process Both
IL-1RI MEKK1 Association Both
IL-1RI MyD88 Association Both
IL-1RI MyD88 Process Both
IL-1RI Pellino1 Process Both
IL-1RI SITPEC Association Both
IL-1RI tab2 Process Both
IL-1RI traf6 Association Both
IL-1RI traf6 Process Both
IL8 p50 Process Both
IL8 RelA-p65 Process Both
IL8 SRC-1 Process Both
importin-alpha3 p50 Association Both
importin-alpha3 RelA-p65 Association Both
IRAK-1 IRAK-2 Association Both
IRAK-1 IRAK-2 Process Both
IRAK-1 IRAK-4 Association Both
IRAK-1 IRAK-4 Dissociation Both
IRAK-1 IRAK-4 Process Both
IRAK-1 lbp Association Both
IRAK-1 lbp Process Both
IRAK-1 LPS Association Both
IRAK-1 LPS Process Both
IRAK-1 MD-2 Association Both
IRAK-1 MD-2 Process Both
IRAK-1 MEKK1 Association Both
IRAK-1 MyD88 Association Both
IRAK-1 MyD88 Process Both
IRAK-1 Pellino1 Dissociation Both
IRAK-1 Pellino1 Process Both
IRAK-1 SITPEC Association Both
IRAK-1 tab2 Dissociation Both
IRAK-1 tab2 Process Both
IRAK-1 TLR4 Association Both
IRAK-1 TLR4 Process Both
IRAK-1 traf6 Association Both
IRAK-1 traf6 Dissociation Both
IRAK-1 traf6 Process Both
IRAK-2 IRAK-4 Association Both
IRAK-2 IRAK-4 Process Both
IRAK-2 MEKK1 Association Both
IRAK-2 MyD88 Association Both
IRAK-2 MyD88 Process Both
IRAK-2 Pellino1 Process Both
IRAK-2 SITPEC Association Both
IRAK-2 tab2 Process Both
IRAK-2 traf6 Association Both
IRAK-2 traf6 Process Both
IRAK-4 MEKK1 Association Both
IRAK-4 MyD88 Association Both
IRAK-4 MyD88 Process Both
IRAK-4 Pellino1 Dissociation Both
IRAK-4 Pellino1 Process Both
IRAK-4 SITPEC Association Both
IRAK-4 tab2 Dissociation Both
IRAK-4 tab2 Process Both
IRAK-4 traf6 Association Both
IRAK-4 traf6 Dissociation Both
IRAK-4 traf6 Process Both
JNK1 MKK4 Process Both
JNK1 MKK7 Association Both
JNK1 MKK7 Process Both
JNK1 TAB1 Process Both
JNK2 MKK4 Process Both
lbp LPS Association Both
lbp LPS Process Both
lbp MD-2 Association Both
lbp MD-2 Process Both
lbp MEKK1 Association Both
lbp MyD88 Association Both
lbp MyD88 Process Both
lbp SITPEC Association Both
lbp tab2 Process Both
lbp TLR4 Association Both
lbp TLR4 Process Both
lbp traf6 Association Both
lbp traf6 Process Both
LPS MD-2 Association Both
LPS MD-2 Process Both
LPS MEKK1 Association Both
LPS MyD88 Association Both
LPS MyD88 Process Both
LPS SITPEC Association Both
LPS tab2 Process Both
LPS TLR4 Association Both
LPS TLR4 Process Both
LPS traf6 Association Both
LPS traf6 Process Both
MD-2 MEKK1 Association Both
MD-2 MyD88 Association Both
MD-2 MyD88 Process Both
MD-2 SITPEC Association Both
MD-2 tab2 Process Both
MD-2 TLR4 Association Both
MD-2 TLR4 Process Both
MD-2 traf6 Association Both
MD-2 traf6 Process Both
MEKK1 MKK7 Process Both
MEKK1 MyD88 Association Both
MEKK1 SITPEC Association Both
MEKK1 SITPEC Process Both
MEKK1 TLR4 Association Both
MEKK1 TNF-alpha Association Both
MEKK1 TNF-alpha Process Both
MEKK1 TNFR1 Association Both
MEKK1 TNFR1 Process Both
MEKK1 TRADD Association Both
MEKK1 TRADD Process Both
MEKK1 TRAF2 Association Both
MEKK1 TRAF2 Process Both
MEKK1 traf6 Association Both
MEKK1 traf6 Process Both
miR-126-3p VCAM1 Process Both
MKK4 MKK7 Process Both
MKK4 TRAF2 Process Both
MKK6 p38alpha Process Both
MKK6 TAB1 Process Both
MKK6 tab2 Process Both
MKK6 TAK1 Process Both
MKK6 traf6 Process Both
MKK7 p38alpha Process Both
MKK7 TNF-alpha Process Both
MKK7 TNFR1 Process Both
MKK7 TRADD Process Both
MKK7 TRAF2 Process Both
MSK1 p50 Process Both
MSK1 RelA-p65 Process Both
MyD88 Pellino1 Process Both
MyD88 SITPEC Association Both
MyD88 ST2 Association Both
MyD88 tab2 Process Both
MyD88 TLR4 Association Both
MyD88 TLR4 Process Both
MyD88 TLR5 Process Both
MyD88 traf6 Association Both
MyD88 traf6 Process Both
NFKBIA p50 Process Both
NFKBIA RelA-p65 Process Both
NIK p62 Association Both
NIK p62 Dissociation Both
NIK p62 Process Both
NIK PKCzeta Association Both
NIK PKCzeta Dissociation Both
NIK PKCzeta Process Both
NIK RIP Association Both
NIK RIP Dissociation Both
NIK RIP Process Both
NIK TNF-alpha Association Both
NIK TNF-alpha Dissociation Both
NIK TNF-alpha Process Both
NIK TNFR1 Association Both
NIK TNFR1 Dissociation Both
NIK TNFR1 Process Both
NIK TRADD Association Both
NIK TRADD Dissociation Both
NIK TRADD Process Both
NIK TRAF2 Association Both
NIK TRAF2 Dissociation Both
NIK TRAF2 Process Both
N-SMase RACK1 Process Both
N-SMase SM Process Both
N-SMase TNF-alpha Process Both
N-SMase TNFR1 Process Both
p105 p50 Dissociation Both
p105 ubiquitin Association Both
p105 ubiquitin Dissociation Both
p38alpha TAB1 Process Both
p50 Pin1 Association Both
p50 PKAc Process Both
p50 RelA-p65 Association Both
p50 RelA-p65 Dissociation Both
p50 RelA-p65 Process Both
p50 S-adenosylhomocysteine Process Both
p50 S-adenosylmethionine Process Both
p50 SELE Process Both
p50 SOCS-1 Association Both
p50 SOCS-1 Dissociation Both
p50 SRC-1 Association Both
p50 SRC-1 Process Both
p50 TNFAIP3 Process Both
p50 Ubc5 Association Both
p50 Ubc5 Process Both
p50 Ubc5A Association Both
p50 Ubc5C Process Both
p50 ubiquitin Association Both
p50 ubiquitin Dissociation Both
p50 ubiquitin Process Both
p50 VCAM1 Process Both
p50 Wip1 Process Both
p62 PKCzeta Association Both
p62 PKCzeta Dissociation Both
p62 PKCzeta Process Both
p62 RIP Association Both
p62 RIP Dissociation Both
p62 RIP Process Both
p62 TNF-alpha Association Both
p62 TNF-alpha Dissociation Both
p62 TNF-alpha Process Both
p62 TNFR1 Association Both
p62 TNFR1 Dissociation Both
p62 TNFR1 Process Both
p62 TRADD Association Both
p62 TRADD Dissociation Both
p62 TRADD Process Both
p62 TRAF2 Association Both
p62 TRAF2 Dissociation Both
p62 TRAF2 Process Both
Pellino1 tab2 Dissociation Both
Pellino1 tab2 Process Both
Pellino1 traf6 Dissociation Both
Pellino1 traf6 Process Both
Pin1 RelA-p65 Association Both
PKAc RelA-p65 Process Both
PKCzeta RIP Association Both
PKCzeta RIP Dissociation Both
PKCzeta RIP Process Both
PKCzeta TNF-alpha Association Both
PKCzeta TNF-alpha Dissociation Both
PKCzeta TNF-alpha Process Both
PKCzeta TNFR1 Association Both
PKCzeta TNFR1 Dissociation Both
PKCzeta TNFR1 Process Both
PKCzeta TRADD Association Both
PKCzeta TRADD Dissociation Both
PKCzeta TRADD Process Both
PKCzeta TRAF2 Association Both
PKCzeta TRAF2 Dissociation Both
PKCzeta TRAF2 Process Both
proCaspase-2 RIP Association Both
proCaspase-2 RIP Dissociation Both
proCaspase-2 TNF-alpha Association Both
proCaspase-2 TNF-alpha Dissociation Both
proCaspase-2 TNFR1 Association Both
proCaspase-2 TNFR1 Dissociation Both
proCaspase-2 TRADD Association Both
proCaspase-2 TRADD Dissociation Both
RACK1 SM Process Both
RACK1 TNF-alpha Association Both
RACK1 TNF-alpha Process Both
RACK1 TNFR1 Association Both
RACK1 TNFR1 Process Both
RelA-p65 S-adenosylhomocysteine Process Both
RelA-p65 S-adenosylmethionine Process Both
RelA-p65 SELE Process Both
RelA-p65 SOCS-1 Association Both
RelA-p65 SOCS-1 Dissociation Both
RelA-p65 SRC-1 Association Both
RelA-p65 SRC-1 Process Both
RelA-p65 TNFAIP3 Process Both
RelA-p65 Ubc5 Association Both
RelA-p65 Ubc5 Process Both
RelA-p65 Ubc5A Association Both
RelA-p65 Ubc5C Process Both
RelA-p65 ubiquitin Association Both
RelA-p65 ubiquitin Dissociation Both
RelA-p65 ubiquitin Process Both
RelA-p65 VCAM1 Process Both
RelA-p65 Wip1 Process Both
RIP tab2 Association Both
RIP tab2 Dissociation Both
RIP tab2 Process Both
RIP tab3 Association Both
RIP tab3 Dissociation Both
RIP tab3 Process Both
RIP TAK1 Association Both
RIP TAK1 Dissociation Both
RIP TAK1 Process Both
RIP TNF-alpha Association Both
RIP TNF-alpha Dissociation Both
RIP TNF-alpha Process Both
RIP TNFR1 Association Both
RIP TNFR1 Dissociation Both
RIP TNFR1 Process Both
RIP TRADD Association Both
RIP TRADD Dissociation Both
RIP TRADD Process Both
RIP TRAF2 Association Both
RIP TRAF2 Dissociation Both
RIP TRAF2 Process Both
RIP ubiquitin Association Both
RIP ubiquitin Dissociation Both
S-adenosylhomocysteine S-adenosylmethionine Process Both
S-adenosylhomocysteine SRC-1 Process Both
S-adenosylmethionine SRC-1 Process Both
SITPEC TLR4 Association Both
SITPEC traf6 Association Both
SITPEC traf6 Process Both
SM TNF-alpha Process Both
SM TNFR1 Process Both
SOCS-1 Ubc5 Association Both
SOCS-1 Ubc5A Association Both
SOCS-1 ubiquitin Association Both
SOCS-1 ubiquitin Dissociation Both
TAB1 tab2 Association Both
TAB1 tab2 Process Both
TAB1 TAK1 Association Both
TAB1 TAK1 Process Both
TAB1 traf6 Association Both
TAB1 traf6 Process Both
tab2 tab3 Association Both
tab2 tab3 Dissociation Both
tab2 tab3 Process Both
tab2 TAK1 Association Both
tab2 TAK1 Dissociation Both
tab2 TAK1 Process Both
tab2 TLR4 Process Both
tab2 TRADD Association Both
tab2 TRADD Dissociation Both
tab2 TRADD Process Both
tab2 TRAF2 Association Both
tab2 TRAF2 Dissociation Both
tab2 TRAF2 Process Both
tab2 traf6 Association Both
tab2 traf6 Dissociation Both
tab2 traf6 Process Both
tab2 ubiquitin Process Both
tab3 TAK1 Association Both
tab3 TAK1 Dissociation Both
tab3 TAK1 Process Both
tab3 TRADD Association Both
tab3 TRADD Dissociation Both
tab3 TRADD Process Both
tab3 TRAF2 Association Both
tab3 TRAF2 Dissociation Both
tab3 TRAF2 Process Both
TAK1 TRADD Association Both
TAK1 TRADD Dissociation Both
TAK1 TRADD Process Both
TAK1 TRAF2 Association Both
TAK1 TRAF2 Dissociation Both
TAK1 TRAF2 Process Both
TAK1 traf6 Association Both
TAK1 traf6 Process Both
TAK1 ubiquitin Association Both
TLR4 traf6 Association Both
TLR4 traf6 Process Both
TNF-alpha TNFR1 Association Both
TNF-alpha TNFR1 Dissociation Both
TNF-alpha TNFR1 Process Both
TNF-alpha TRADD Association Both
TNF-alpha TRADD Dissociation Both
TNF-alpha TRADD Process Both
TNF-alpha TRAF2 Association Both
TNF-alpha TRAF2 Dissociation Both
TNF-alpha TRAF2 Process Both
TNF-alpha ubiquitin Association Both
TNF-alpha ubiquitin Dissociation Both
TNFR1 TRADD Association Both
TNFR1 TRADD Dissociation Both
TNFR1 TRADD Process Both
TNFR1 TRAF2 Association Both
TNFR1 TRAF2 Dissociation Both
TNFR1 TRAF2 Process Both
TNFR1 ubiquitin Association Both
TNFR1 ubiquitin Dissociation Both
TRADD TRAF2 Association Both
TRADD TRAF2 Dissociation Both
TRADD TRAF2 Process Both
TRADD ubiquitin Association Both
TRADD ubiquitin Dissociation Both
TRAF2 ubiquitin Association Both
TRAF2 ubiquitin Dissociation Both
traf6 ubiquitin Association Both
traf6 ubiquitin Process Both
Ubc5 Ubc5A Association Both
Ubc5 Ubc5C Process Both
Ubc5 ubiquitin Association Both
Ubc5 ubiquitin Process Both
Ubc5A ubiquitin Association Both

ENSG00000090006 3.6 12 71893 0.90934
ENSG00000119681 3.6 12 71893 0.90934
ENSG00000168056 3.6 12 71893 0.90934
ENSG00000134759 3.6 12 71893 0.90934
ENSG00000115415 3.6 12 71893 0.90934
ENSG00000105397 3.6 12 71893 0.90934
ENSG00000110324 3.6 12 71893 0.90934
ENSG00000136634 3.6 12 71893 0.90934
ENSG00000162434 3.6 12 71893 0.90934
ENSG00000243646 3.6 12 71893 0.90934
ENSG00000164400 3.6 12 71893 0.90934
ENSG00000115008 3.6 12 71893 0.90934
ENSG00000110944 3.6 12 71893 0.90934
ENSG00000138378 3.6 12 71893 0.90934
ENSG00000113580 3.6 12 71893 0.90934
ENSG00000134352 3.6 12 71893 0.90934
ENSG00000160712 3.6 12 71893 0.90934
ENSG00000069702 3.6 12 71893 0.90934
ENSG00000163513 3.6 12 71893 0.90934
ENSG00000017427 3.6 12 71893 0.90934
ENSG00000168036 3.6 12 71893 0.90934
ENSG00000164761 3.6 12 71893 0.90934
ENSG00000164136 3.6 12 71893 0.90934
ENSG00000118689 3.6 12 71893 0.90934
ENSG00000175387 3.6 12 71893 0.90934
ENSG00000108691 3.6 12 71893 0.90934
ENSG00000157404 3.6 12 71893 0.90934
ENSG00000160791 3.6 12 71893 0.90934
ENSG00000039068 3.6 12 71893 0.90934
ENSG00000112116 3.6 12 71893 0.90934
ENSG00000112115 3.6 12 71893 0.90934
ENSG00000090339 3.6 12 71893 0.90934
ENSG00000102245 3.6 12 71893 0.90934
ENSG00000173327 3.6 12 71893 0.90934
ENSG00000144381 3.6 12 71893 0.90934
ENSG00000168610 3.6 12 71893 0.90934
ENSG00000149968 3.6 12 71893 0.90934
ENSG00000006062 5.46 12 70106 0.74578536
ENSG00000106683 3.6 12 71893 0.90934
ENSG00000111321 5.46 12 70106 0.745759
ENSG00000226979 5.46 12 70106 0.745759
ENSG00000227507 5.46 12 70106 0.745759
ENSG00000115541 3.6 12 71893 0.90934
ENSG00000164305 3.6 12 71893 0.90934
ENSG00000113525 3.6 12 71893 0.90934
ENSG00000064012 3.6 12 71893 0.90934
ENSG00000072062 5.6 12 70973 0.807201
ENSG00000232810 3.6 12 71893 0.90934
ENSG00000067182 3.6 12 71893 0.90934
ENSG00000108094 6.12 12 70584 0.7465518
ENSG00000115457 6.75 12 70055 0.61936754
ENSG00000173039 6.75 12 70046 0.6259042
ENSG00000105810 6.75 12 70044 0.6250095
ENSG00000147162 6.75 12 70045 0.6155797
ENSG00000164088 6.75 12 70029 0.6124364
ENSG00000005381 5.3999996 12 71017 0.82925606
ENSG00000107968 6.6 12 70129 0.71335024
ENSG00000110330 5.5 12 70517 0.7119078
ENSG00000067900 6.75 12 70037 0.6123565
ENSG00000104365 6.75 12 70119 0.6526765
ENSG00000134058 6.75 12 70030 0.6123358
ENSG00000269335 5.75 12 70869 0.71404743
ENSG00000131788 5.76 12 70778 0.71407497
ENSG00000163702 6.75 12 70099 0.612196
ENSG00000177663 6.75 12 70099 0.612196
ENSG00000213341 6.75 12 70125 0.6153272
ENSG00000055208 6.75 12 70099 0.612196
ENSG00000056972 6.75 12 70099 0.612196
ENSG00000131323 7.035 12 65994 0.5407338
ENSG00000175104 6.75 12 70099 0.612196
ENSG00000162924 9.9 12 59326 0.46628165
ENSG00000135341 5.76 12 70043 0.6245046
ENSG00000129559 8.28 12 66741 0.54859954
ENSG00000173801 7.56 12 68114 0.59836376
ENSG00000105329 3.6 12 71893 0.90934
ENSG00000149591 7.6 12 68077 0.59836614
ENSG00000167749 7.6 12 68070 0.5983616
ENSG00000115170 7.5950003 12 68069 0.5983511
ENSG00000152484 7.6 12 68084 0.5983578
ENSG00000131653 6.8 12 69963 0.63348943
ENSG00000121989 7.5600004 12 68115 0.5983318
ENSG00000122641 7.5600004 12 68115 0.5983318
ENSG00000135503 7.5600004 12 68115 0.5983318
ENSG00000172349 7.6 12 68079 0.5983425
ENSG00000160633 7.6 12 68067 0.598348
ENSG00000141552 7.6 12 68076 0.598261
ENSG00000172840 7.5950003 12 68080 0.5983457
ENSG00000139567 7.5950003 12 68070 0.5983349
ENSG00000136807 7.5950003 12 68107 0.60283357
ENSG00000100234 7.5599995 12 68137 0.5983164
ENSG00000164850 3.6 12 71894 0.909338
ENSG00000112799 3.6 12 71894 0.909338
ENSG00000134061 3.6 12 71894 0.909338
ENSG00000169118 6.8499994 12 69866 0.63015866
ENSG00000115718 5.91 12 70681 0.71089166
ENSG00000178568 7.5950003 12 68082 0.5982364
ENSG00000065361 7.5950003 12 68082 0.59823585
ENSG00000141736 7.5950003 12 68082 0.5982351
ENSG00000104856 4.32 2 78 0.25144747
ENSG00000135960 5.76 12 69263 0.62076813
ENSG00000089041 6.6 12 70129 0.7012792
ENSG00000100079 6.6 12 70130 0.70127815
ENSG00000164951 7.5950003 12 68069 0.5983471
ENSG00000180772 5.91 12 70682 0.7108893
ENSG00000095739 6.6 12 70129 0.70127857
ENSG00000107014 6.6 12 70130 0.7012774
ENSG00000107779 7.5950003 12 68083 0.5980402
ENSG00000150093 9.585 12 60076 0.41584295
ENSG00000105647 7.9999995 12 66901 0.5182761
ENSG00000128342 6.6 12 70129 0.70127815
ENSG00000176797 6.6 12 70130 0.7012766
ENSG00000177243 6.6 12 70130 0.7012766
ENSG00000115687 6.75 12 70172 0.6347166
ENSG00000112425 6.75 12 70180 0.6347163
ENSG00000043093 9.27 12 63476 0.45494947
ENSG00000171855 6.6 12 70138 0.7012685
ENSG00000145675 7.9999995 12 66901 0.5182743
ENSG00000104814 7.5600004 12 65212 0.51734453
ENSG00000136279 7.5600004 12 65212 0.51734453
ENSG00000010671 9.599999 12 60063 0.4158373
ENSG00000101977 7.6 12 68110 0.59817326
ENSG00000108389 7.5950003 12 68134 0.59828806
ENSG00000157450 9.38 12 62732 0.45513147
ENSG00000204209 7.5599995 12 68194 0.5978195
ENSG00000100393 8 12 67011 0.5181211
ENSG00000110958 9.599999 12 60057 0.41586527
ENSG00000126351 9.599999 12 60093 0.41587228
ENSG00000174775 9.57 12 60167 0.41561633
ENSG00000100983 9.599999 12 60601 0.41573972
ENSG00000180370 7.5950003 12 68408 0.59760123
ENSG00000118503 3.6 12 71893 0.90934
ENSG00000197081 9 12 63755 0.42712894
ENSG00000131196 7.95 12 67021 0.517943
ENSG00000169194 3.6 12 71893 0.90934
ENSG00000113520 3.6 12 71893 0.90934
ENSG00000068903 7.8 12 67853 0.554528
ENSG00000147099 7.95 12 67030 0.5179252
ENSG00000150782 3.6 12 71893 0.90934
ENSG00000159110 9 12 63761 0.42710644
ENSG00000007171 3.6 12 71893 0.90934
ENSG00000048052 7.95 12 67033 0.51792264
ENSG00000115594 3.6 12 71893 0.90934
ENSG00000185338 6.91 12 69124 0.6298157
ENSG00000082146 9.595 12 60290 0.41571394
ENSG00000061273 7.95 12 67065 0.51789963
ENSG00000094631 7.95 12 67032 0.51791775
ENSG00000108840 7.95 12 67030 0.5179232
ENSG00000156711 7.5950003 12 68171 0.59766006
ENSG00000117399 9.599999 12 60352 0.41544947
ENSG00000188130 7.5950003 12 68166 0.59763104
ENSG00000108443 9.585 12 61285 0.41531238
ENSG00000117984 7.95 12 67071 0.51790935
ENSG00000213281 9.57 12 60140 0.4156918
ENSG00000185104 5.76 12 70777 0.7104392
ENSG00000129422 9 12 63755 0.4271303
ENSG00000263528 7.75 12 68025 0.5711993
ENSG00000177606 9.285 10 49709 0.32360092
ENSG00000198900 9.285 10 49709 0.32360092
ENSG00000137834 5.76 12 70777 0.710434
ENSG00000111653 6.91 12 69105 0.62207466
ENSG00000011275 8.91 12 59454 0.34724462
ENSG00000171206 9.495 12 60595 0.43240014
ENSG00000187391 5.76 12 70784 0.7104409
ENSG00000144802 7.92 12 67218 0.51772976
ENSG00000176697 5.76 12 70777 0.7104282
ENSG00000138794 5.76 12 70777 0.7104279
ENSG00000106624 5.76 12 70785 0.7104448
ENSG00000104408 9 12 63838 0.42702994
ENSG00000131080 8.85 12 65024 0.43020087
ENSG00000129988 5.76 12 70790 0.71043706
ENSG00000157227 5.76 12 70777 0.71042585
ENSG00000049130 7.92 12 67218 0.5177293
ENSG00000173163 8.610001 12 59328 0.3733167
ENSG00000177426 7.92 12 67220 0.5177254
ENSG00000100380 8.969999 12 63859 0.42679292
ENSG00000153233 5.76 12 70777 0.7104353
ENSG00000141753 7.92 12 67218 0.5177292
ENSG00000082074 9.599999 12 60086 0.41582003
ENSG00000275302 7.92 12 67218 0.5177297
ENSG00000126583 9 12 63769 0.42712083
ENSG00000154229 9 12 63769 0.42712083
ENSG00000166501 9 12 63769 0.42712083
ENSG00000095015 8.85 12 65059 0.43016466
ENSG00000130159 8.85 12 65059 0.43016466
ENSG00000213658 9.599999 12 60116 0.41576496
ENSG00000150630 8.969999 12 63866 0.42678547
ENSG00000106615 9.57 12 60071 0.4158295
ENSG00000225950 5.76 12 70777 0.71043473
ENSG00000146678 5.76 12 70777 0.710435
ENSG00000271503 7.92 12 67218 0.5177286
ENSG00000075213 7.92 12 67218 0.51772624
ENSG00000157933 7.92 12 67218 0.5177291
ENSG00000183691 5.76 12 70778 0.71040905
ENSG00000043462 9.599999 12 60148 0.41575575
ENSG00000051523 8.985001 12 63770 0.4270362
ENSG00000100365 8.985001 12 63770 0.4270362
ENSG00000116701 8.985001 12 63770 0.4270362
ENSG00000136238 8.985001 12 63770 0.4270362
ENSG00000142765 8.985001 12 63770 0.4270362
ENSG00000158517 8.985001 12 63770 0.4270362
ENSG00000165168 8.985001 12 63770 0.4270362
ENSG00000113721 5.76 12 70778 0.71040905
ENSG00000197635 7.92 12 67222 0.517722
ENSG00000134853 5.76 12 70778 0.7104186
ENSG00000121653 7.92 12 67218 0.5177258
ENSG00000102524 8.91 11 37216 0.2654545
ENSG00000213928 7.92 12 67219 0.5177216
ENSG00000121879 7.92 12 67220 0.5177101
ENSG00000078369 7.98 9 31781 0.24260649
ENSG00000115461 7.92 12 67218 0.5177259
ENSG00000185499 7.92 12 67218 0.5177259
ENSG00000170581 7.92 12 67219 0.517722
ENSG00000142166 7.92 12 67219 0.51772016
ENSG00000158813 7.92 12 63549 0.4400373
ENSG00000079385 8.969999 12 63900 0.42671067
ENSG00000187098 8.969999 12 63908 0.4267764
ENSG00000129315 7.92 12 67222 0.51771617
ENSG00000196083 7.92 12 67221 0.5176931
ENSG00000099942 10 12 57637 0.335366
ENSG00000107263 10 12 57637 0.335366
ENSG00000187266 10 12 57637 0.335366
ENSG00000124762 7.92 12 67219 0.5177215
ENSG00000277632 7.92 12 67219 0.51770365
ENSG00000120868 10 12 57686 0.33529928
ENSG00000132906 10 12 57686 0.33529928
ENSG00000172115 10 12 57686 0.33529928
ENSG00000154310 7.92 12 67220 0.51771235
ENSG00000131089 7.92 12 67236 0.5176874
ENSG00000102547 9.835001 10 34919 0.24541828
ENSG00000118046 9.835001 10 34919 0.24541828
ENSG00000135932 9.835001 10 34919 0.24541828
ENSG00000266173 9.835001 10 34919 0.24541828
ENSG00000140299 7.92 12 67235 0.5176878
ENSG00000197461 7.92 12 67233 0.5176887
ENSG00000127948 9.795 10 43756 0.24303655
ENSG00000109320 7.695 9 42750 0.24338467
ENSG00000088387 7.92 12 67237 0.5176855
ENSG00000085276 7.92 12 67218 0.517708
ENSG00000180228 7.92 12 67232 0.51767194
ENSG00000017797 7.92 12 67239 0.51766765
ENSG00000105974 8.969999 12 63876 0.4267289
ENSG00000140575 7.92 12 67222 0.51771337
ENSG00000171560 9.889999 10 43781 0.24304931
ENSG00000166949 9 12 63756 0.42712975
ENSG00000070831 7.92 12 67220 0.5176907
ENSG00000158092 7.92 12 67219 0.51770896
ENSG00000168067 7.995 9 31776 0.24262741
ENSG00000002330 9.93 10 43578 0.24308331
ENSG00000111276 7.9749994 9 31837 0.24258348
ENSG00000123374 7.9749994 9 31837 0.24258348
ENSG00000105141 9.9 12 59349 0.33481878
ENSG00000196642 8.91 12 64087 0.42654973
ENSG00000163935 9.9 12 59330 0.33482593
ENSG00000157625 7.92 12 64880 0.44248962
ENSG00000178522 9.9 12 59330 0.33482286
ENSG00000204628 9 12 63756 0.4271173
ENSG00000088832 8.969999 12 63860 0.42677236
ENSG00000108622 9.889999 10 43734 0.24306636
ENSG00000137802 9.9 12 59330 0.33482626
ENSG00000111802 9.225 12 55447 0.33578593
ENSG00000171522 9.9 12 59330 0.33482534
ENSG00000067082 8.91 12 64088 0.42654967
ENSG00000162733 8.91 12 64102 0.42653918
ENSG00000110651 9.9 12 59332 0.33482435
ENSG00000109458 8.969999 12 63910 0.42671496
ENSG00000019991 9.9 12 59334 0.33482125
ENSG00000127914 9.9 12 59335 0.3348233
ENSG00000091879 9.91 10 43975 0.24301484
ENSG00000103056 9.9 12 59336 0.33482343
ENSG00000132024 9.9 12 59333 0.3348239
ENSG00000138668 8.91 12 59459 0.35119116
ENSG00000103490 9.9 12 59334 0.33482435
ENSG00000264522 8.61 12 59380 0.36004668
ENSG00000141867 9.455 10 48628 0.25022906
ENSG00000143437 9.780001 10 43703 0.24304433
ENSG00000020426 9.38 10 48880 0.2501911
ENSG00000134480 9.38 10 48880 0.2501911
ENSG00000184990 9.9 12 59367 0.33481124





































































































































































































































































































































Table S4: IBD target genes, with source of data
ID IBD importance IBD Causal IBD Correlative IBD Mechanism IBD Negative
TNF 10 + + +
TNFRSF11B 10 + + +
TNFRSF18 10 + + +
TNFRSF1A 10 + + +
TNFRSF4 10 + + +
TNFRSF6B 10 + + +
TNFRSF9 10 + + +
TNFSF11 10 + + +
TNFSF14 10 + + +
TNFSF15 10 + + +
TNFSF18 10 + + +
TNFSF4 10 + + +
IL10 10 + + + +
IL13 10 + + + +
IL15 10 + + + +
IL15RA 10 + + + +
IL17A 10 + + + +
IL17F 10 + + + +
IL18 10 + + + +
IL18RAP 10 + + + +
IL1A 10 + + + +
IL1B 10 + + + +
IL1R1 10 + + + +
IL1RN 10 + + + +
IL21 10 + + + +
IL22 10 + + + +
IL23R 10 + + + +
IL25 10 + + + +
IL26 10 + + + +
IL27 10 + + + +
IL31RA 10 + + + +
IL4 10 + + + +
IL5 10 + + + +
IL6 10 + + + +
IL6ST 10 + + + +
CCL11 8 + + + +
CCL13 8 + + + +
CCL17 8 + + + +
CCL2 8 + + + +
CCL20 8 + + + +
CCL26 8 + + + +
CCR5 8 + + + +
CCR6 8 + + + +
CX3CL1 8 + + + +
CXCL16 8 + + + +
CXCL6 8 + + + +
CXCL8 8 + + + +
CXCR5 8 + + + +
MAP3K8 5 + +
MAPK1 5 + +
MAPK3 5 + +
MAPK8 5 + +
SELP 5 + +
SELPLG 5 + +
STAT1 5 + +
STAT3 5 + +
STAT4 5 + +
STAT6 5 + +
IFNAR1 4 + +
IFNG 4 + +
IFNGR2 4 + +
NOD1 4 + +
NOD2 4 + +
VEGFA 4 + +
HSPA6 3 + +
HSPD1 3 + +
ICAM1 3 + +
IL12A 3 + +
IL12B 3 + +
MMP1 3 + +
MMP10 3 + +
MMP2 3 + +
MMP3 3 + +
MMP7 3 + +
MMP9 3 + +
TGFB1 3 + +
TLR2 3 + +
TLR3 3 + +




BMP7 3 + +
EPO 3





GPX2 2 + +
GPX4 2 + +
IGF1 2 + +
IGSF6 2 + +
IL2 2 + +
IL2RA 2 + +
KIT 2 + +
MPO 2 + +
NFKB2 2 + +
NOS2 2 + +
PRKCB 2 + +
PTK2B 2 + +
PTPN22 2 + +
REL 2 + +
RELA 2 + +
SELE 2 + +
SELL 2 + +
SMAD3 2 + +
TAB1 2 + +



















































IBD Preventative IBD Prognosis IBD Target IBD GWAS prognosis IBD GWAS susceptablity
+ + + + +
+ + + + +
+ + + + +
+ + + + +
+ + + + +
+ + + + +
+ + + + +
+ + + + +
+ + + + +
+ + + + +
+ + + + +
+ + + + +
+ + + +
+ + + +
+ + + +
+ + + +
+ + + +
+ + + +
+ + + +
+ + + +
+ + + +
+ + + +
+ + + +
+ + + +
+ + + +
+ + + +
+ + + +
+ + + +
+ + + +
+ + + +
+ + + +
+ + + +
+ + + +
+ + + +





























































Table S5: List of IBD key-nodes, potential therapeutic targets for IBD
ID Gene symbol Score FDR Z-Score Ranks sum
ENSG00000111537 IFNG 0.90934 0 25.515682 2
ENSG00000148344 PTGES 0.90934 0 25.109789 20
ENSG00000109471 IL2 0.90934 0 25.109789 24
ENSG00000174175 SELP 0.90934 0 23.785404 34
ENSG00000137462 TLR2 0.90934 0 17.603453 51
ENSG00000136869 TLR4 0.90934 0 17.603453 53
ENSG00000006210 CX3CL1 0.90934 0 25.109789 62
ENSG00000130427 EPO 0.90934 0 16.325098 68
ENSG00000026508 CD44 0.90934 0 15.644362 73
ENSG00000136689 IL1RN 0.90934 0 15.893072 79
ENSG00000169429 CXCL8 0.90934 0 14.898232 84
ENSG00000115009 CCL20 0.90934 0 14.649521 88
ENSG00000115353 TACR1 0.90934 0 14.649521 92
ENSG00000113302 IL12B 0.90934 0 14.649521 94
ENSG00000125538 IL1B 0.90934 0 9.924029 126
ENSG00000100985 MMP9 0.90934 0 8.680479 132
ENSG00000149269 PAK1 0.90934 0 8.444952 143
ENSG00000166888 STAT6 0.90934 0 25.515682 153
ENSG00000136244 IL6 0.90934 0 9.177899 155
ENSG00000164400 CSF2 0.90934 0 6.7536426 174
ENSG00000115008 IL1A 0.90934 0 6.7536426 180
ENSG00000113580 NR3C1 0.90934 0 19.889582 192
ENSG00000017427 IGF1 0.90934 0 6.512027 202
ENSG00000112715 VEGFA 0.90934 0 14.649521 206
ENSG00000164761 TNFRSF11B 0.90934 0 12.16242 208
ENSG00000164136 IL15 0.90934 0 5.1354814 210
ENSG00000118689 FOXO3 0.90934 0 8.444952 214
ENSG00000175387 SMAD2 0.90934 0 10.42145 216
ENSG00000108691 CCL2 0.90934 0 13.903391 218
ENSG00000160791 CCR5 0.90934 0 22.46102 224
ENSG00000039068 CDH1 0.90934 0 3.7350864 226
ENSG00000112115 IL17A 0.90934 0 9.924029 233
ENSG00000137752 CASP1 0.90934 0 3.4077682 235
ENSG00000090339 ICAM1 0.90934 0 3.1813836 239
ENSG00000102245 CD40LG 0.90934 0 3.1813836 243
ENSG00000100030 MAPK1 0.90934 0 17.347782 251
ENSG00000102882 MAPK3 0.90934 0 24.315157 260
ENSG00000144381 HSPD1 0.90934 0 2.5022295 269
ENSG00000115415 STAT1 0.90934 0 25.515682 273
ENSG00000149968 MMP3 0.90934 0 2.4914422 275
ENSG00000136634 IL10 0.90934 0 2.4914422 277
ENSG00000113525 IL5 0.90934 0 2.2562785 288
ENSG00000168036 CTNNB1 0.90934 0 25.515682 294
ENSG00000232810 TNF 0.90934 0 2.2562785 296
ENSG00000064012 CASP8 0.90934 0 24.050282 300
ENSG00000067182 TNFRSF1A 0.90934 0 2.031885 322
ENSG00000087245 MMP2 0.90934 0 8.92919 324
ENSG00000138378 STAT4 0.90934 0 5.862493 326
ENSG00000108094 CUL2 0.7465518 0.01 2.1583393 330
ENSG00000005381 MPO 0.8292561 0.01 1.8166571 354
ENSG00000105329 TGFB1 0.90934 0 3.1813836 429
ENSG00000168610 STAT3 0.90934 0 13.903391 458
ENSG00000107643 MAPK8 0.90934 0 19.889582 460
ENSG00000164850 GPER1 0.909338 0 1.2649971 460
ENSG00000118503 TNFAIP3 0.90934 0 1.1343101 528
ENSG00000169194 IL13 0.90934 0 5.862493 530
ENSG00000113520 IL4 0.90934 0 8.203337 532
ENSG00000150782 IL18 0.90934 0 3.7350864 535
ENSG00000007171 NOS2 0.90934 0 1.1343101 537
ENSG00000115594 IL1R1 0.90934 0 2.2562785 539
ENSG00000142208 AKT1 0.90934 0 15.644362 541
ENSG00000157404 KIT 0.90934 0.04 6.7536426 573
Table S6: IBD key-nodes and their associated PASS activities
Gene symbol ID Maximal radius Score Z-Score FDR Ranks sum
IFNG ENSG00000111537 3.6 0.90934 25.515682 0 2
PTGES ENSG00000148344 3.6 0.90934 25.109789 0 20
IL2 ENSG00000109471 3.6 0.90934 25.109789 0 24
SELP ENSG00000174175 3.6 0.90934 23.785404 0 34
TLR2 ENSG00000137462 3.6 0.90934 17.603453 0 51
TLR4 ENSG00000136869 3.6 0.90934 17.603453 0 53
CD44 ENSG00000026508 3.6 0.90934 15.6443615 0 73
CXCL8 ENSG00000169429 3.6 0.90934 14.8982315 0 84
IL12B ENSG00000113302 3.6 0.90934 14.649521 0 94
IL1B ENSG00000125538 3.6 0.90934 9.924029 0 126
MMP9 ENSG00000100985 3.6 0.90934 8.680479 0 132
PAK1 ENSG00000149269 3.6 0.90934 8.444952 0 143
STAT6 ENSG00000166888 3.6 0.90934 25.515682 0 153
IL6 ENSG00000136244 3.6 0.90934 9.177899 0 155
CSF2 ENSG00000164400 3.6 0.90934 6.7536426 0 174
IL1A ENSG00000115008 3.6 0.90934 6.7536426 0 180
IGF1 ENSG00000017427 3.6 0.90934 6.512027 0 202
VEGFA ENSG00000112715 3.6 0.90934 14.649521 0 206
IL15 ENSG00000164136 3.6 0.90934 5.1354814 0 210
CCR5 ENSG00000160791 3.6 0.90934 22.46102 0 224
CDH1 ENSG00000039068 3.6 0.90934 3.7350864 0 226
IL17A ENSG00000112115 3.6 0.90934 9.924029 0 233
CASP1 ENSG00000137752 3.6 0.90934 3.4077682 0 235
ICAM1 ENSG00000090339 3.6 0.90934 3.1813836 0 239
MAPK1 ENSG00000100030 3.6 0.90934 17.347782 0 251
MAPK3 ENSG00000102882 3.6 0.90934 24.315157 0 260
HSPD1 ENSG00000144381 3.6 0.90934 2.5022295 0 269
STAT1 ENSG00000115415 3.6 0.90934 25.515682 0 273
MMP3 ENSG00000149968 3.6 0.90934 2.4914422 0 275
IL10 ENSG00000136634 3.6 0.90934 2.4914422 0 277
IL5 ENSG00000113525 3.6 0.90934 2.2562785 0 288
CTNNB1 ENSG00000168036 3.6 0.90934 25.515682 0 294
TNF ENSG00000232810 3.6 0.90934 2.2562785 0 296
CASP8 ENSG00000064012 3.6 0.90934 24.050282 0 300
MMP2 ENSG00000087245 3.6 0.90934 8.92919 0 324
STAT4 ENSG00000138378 3.6 0.90934 5.862493 0 326
MPO ENSG00000005381 5.3999996 0.82925606 1.8166571 0.006 354
TGFB1 ENSG00000105329 3.6 0.90934 3.1813836 0 429
STAT3 ENSG00000168610 3.6 0.90934 13.903391 0 458
MAPK8 ENSG00000107643 3.6 0.90934 19.889582 0 460
IL13 ENSG00000169194 3.6 0.90934 5.862493 0 530
IL4 ENSG00000113520 3.6 0.90934 8.203337 0 532
IL18 ENSG00000150782 3.6 0.90934 3.7350864 0 535
NOS2 ENSG00000007171 3.6 0.90934 1.1343101 0 537
AKT1 ENSG00000142208 3.6 0.90934 15.6443615 0 541

















































Interferon agonist,Interferon antagonist,Interferon gamma antagonist,Interferon inducer
Prostaglandin-E synthase inhibitor,Prostaglandin-E2 synthase 1 inhibitor
Interleukin 2 agonist,Interleukin 2 antagonist,Interleukin agonist,Interleukin antagonist
Cell adhesion molecule inhibitor,Selectin P antagonist,Selectin antagonist
Toll-Like receptor 2 agonist,Toll-Like receptor 2 antagonist,Toll-Like receptor agonist,Toll-Like receptor antago
Toll-Like receptor 4 antagonist,Toll-Like receptor agonist,Toll-Like receptor antagonist
Cell adhesion molecule inhibitor
Interleukin 8 antagonist,Interleukin agonist,Interleukin antagonist
Interleukin 12 agonist,Interleukin agonist,Interleukin antagonist
Interleukin 1 antagonist,Interleukin 1b antagonist,Interleukin agonist,Interleukin antagonist
Collagenase inhibitor,Gelatinase inhibitor,Matrix metalloproteinase inhibitor,Metalloproteinase inhibitor,Meta  
Protein-serine-threonine kinase inhibitor,p21-activated kinase 1 inhibitor,p21-activated kinase inhibitor
Transcription factor STAT inhibitor,Transcription factor STAT6 inhibitor
Interleukin 6 antagonist,Interleukin agonist,Interleukin antagonist
Colony stimulating factor agonist,Colony stimulating factor antagonist,Granulocyte macrophage colony stimul         
Interleukin 1 antagonist,Interleukin 1a antagonist,Interleukin agonist,Interleukin antagonist
Insulin like growth factor 1 agonist
Endothelial growth factor antagonist
Interleukin agonist,Interleukin antagonist
CC chemokine 5 receptor agonist,CC chemokine 5 receptor antagonist,CC chemokine receptor agonist,CC chem       
Cadherin antagonist,Cell adhesion molecule inhibitor
Interleukin agonist,Interleukin antagonist
Interleukin 1 beta converting enzyme inhibitor
Cell adhesion molecule inhibitor,ICAM 1 antagonist
MAP kinase 1 inhibitor,MAP kinase inhibitor,MAP kinase stimulant
MAP kinase 3 inhibitor,MAP kinase inhibitor,MAP kinase stimulant
Chaperonin ATPase inhibitor
Transcription factor STAT inhibitor,Transcription factor STAT1 inhibitor
Matrix metalloproteinase 3 (membrane-type) inhibitor,Matrix metalloproteinase inhibitor,Metalloproteinase  
Interleukin 10 agonist,Interleukin 10 antagonist,Interleukin agonist,Interleukin antagonist
Interleukin 5 antagonist,Interleukin agonist,Interleukin antagonist
Catenin beta inhibitor
Tumour necrosis factor alpha antagonist,Tumour necrosis factor alpha release inhibitor,Tumour necrosis facto  
Caspase 8 inhibitor,Caspase 8 stimulant
Collagenase inhibitor,Gelatinase inhibitor,Matrix metalloproteinase 2 (membrane-type) inhibitor,Matrix meta    
Transcription factor STAT inhibitor
Myeloperoxidase inhibitor,Peroxidase inhibitor
Transforming growth factor agonist,Transforming growth factor antagonist,Transforming growth factor beta 1              
Transcription factor STAT inhibitor,Transcription factor STAT3 inhibitor
JNK mitogen-activated protein kinase inhibitor,MAP kinase 8 inhibitor,MAP kinase inhibitor,MAP kinase stimul
Interleukin agonist,Interleukin antagonist
Interleukin 4 antagonist,Interleukin agonist,Interleukin antagonist
Interleukin agonist,Interleukin antagonist
Inducible nitric oxide synthase inhibitor,Inducible nitric-oxide synthase inhibitor,Nitric-oxide synthase inhibitor   
Protein kinase (PKA_comma_ PKC_comma_ AKT_comma_ GRK_comma_ AGC-related_comma_ RSK_comma_               
Protein-tyrosine kinase (PTK_comma_ not ETK_comma_ WZC) inhibitor,Proto-oncogene tyrosine-protein kina        
         ating factor agonist,Granulocyte macrophage colony stimulating factor antagonist,Hydrolase inhibito
          1 agonist,Transforming growth factor beta 1 antagonist,Transforming growth factor beta agonist,Tran     
       _ DBF2_comma_ SGK) inhibitor,Protein kinase B alpha inhibitor,Protein kinase B inhibitor,Protein kina     
                  se B stimulant,Protein-serine-threonine kinase inhibitor
